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Abstract
Delivery of vitamin D3 (VD3) in foods should exhibit desirable physicochemical characteristics
and enhance nutritional significance. To incorporate lipophilic VD3 in beverages,
micro/nanoencapsulation of VD in food biopolymers stable at a wide pH range is a potential
strategy. Gum arabic (GA), a highly branched arabinogalactan with a conjugated peptide, was
investigated as a potential VD3 carrier in this dissertation with objectives to determine (1) optimum
conditions of encapsulating VD3 in GA to maximize loading and characterize physicochemical
properties, (2) in vitro bioaccessibility of encapsulated VD3 in optimized formulation, and (3)
absorption of VD3 after a single high-dose (300 µg) and daily-dose (60 µg d-1, 2-wks) oral
supplementation by measuring 25(OH)D levels in Sprague-Dawley rats. To encapsulate VD3, GA
solution was prepared at 5% (w/v) in deionized water, VD3 solutions were prepared separately in
5 mL ethanol corresponding to 0.03-6.0% mass of GA. VD3 solution was added dropwise into 50
mL of the GA solution while blending at 8,000 rpm for 3 min and then 10,000 rpm for 2 min and
freeze-dried. The optimized formulation had an encapsulation efficiency of 71.3% and a loading
capacity of 3.44%. As pH increased from 2.0-7.4, the average hydrodynamic diameter decreased
from 238.1 to 81.3 nm; whereas the polydispersity index increased from 0.372-0.478, and zetapotential increased its magnitude from -3.09 to -30.97 mV. No precipitation was observed for all
dispersions during 100-d storage at 3 °C. In vitro bioaccessibility of encapsulated VD3 was
95.76%, compared to 68.98% for non-encapsulated VD3 (p < 0.05). The in vivo pharmacokinetic
study after oral gavage of 300 µg VD3 showed that the area-under-curve in 48 h of the
encapsulation treatment was 4.32-fold of the non-encapsulated VD3 and more than twice higher
than the physical mixture. For rats given a daily-dose of 60 µg VD3 d-1 for 2 weeks, the serum
25(OH)D levels of rats that received capsules versus physical mixture showed an increase by 50%
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and 65%, respectively, when compared with the non-encapsulated VD3 group. The current work
demonstrates that the studied encapsulation system may be used to fortify VD3 in beverages with
a wide pH range.

Keywords: cholecalciferol, gum acacia, encapsulation, physicochemical properties, absorption
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Chapter 1 Introduction and literature review

1

Encapsulation of lipophilic nutrients has the aim to improve stability in final products and
release in the small intestines for absorption. Encapsulation is simply defined as a process to
entrap one or more substances, (e.g., active agent), within another substance, commonly referred
to as a carrier material (Fang and Bhandari 2010). Vitamin D (VD) is one of four fat-soluble
vitamins (e.g., A, D, E, and K). VD is unique in that it is not strictly defined as a vitamin because
it can be synthesized in the skin upon exposure to ultraviolet B (UVB; 290-315 nm) rays from the
sun, thereby, classifying VD more as a prohormone (a precursor of an active hormone) (Chen and
others 2007; Holick and Chen 2008). However, VD deficiency is increasingly being reported and
may be attributed to various factors including not getting enough sunlight exposure and/or limited
food choices (Calvo and Whiting 2013; Dwyer and others 2014).
The importance of getting adequate VD in the diet has prompted the US Food and Drug
Administration (FDA) to implement changes in the nutrition labels to replace vitamins A and C
with D. Beginning January 1, 2020, the VD level (zero or added amount) in the Nutrition Facts
Label of packaged foods must be clearly labeled (www.fda.gov). Therefore, improving delivery
of VD by encapsulation in a hydrophilic carrier material to enhance dispersibility in beverages
may increase VD accessibility.
Beverages are one of the fastest growing food sectors and may provide a good medium for
VD fortification. Of the two forms of VD (VD2 vs VD3), VD3 is 2-3 times more effective than
VD2 at raising and maintaining circulating 25(OH)D levels (Tripkovic and others 2012). The
focus of this study is to encapsulate VD3 in gum arabic (GA), a water-soluble matrix. GA is
currently not used alone as an encapsulating matrix for VD. This literature review will therefore
include an introduction to VD, its structure, stability, and types of carrier materials that have been
used to encapsulate VD. Similarly reviewed will be the encapsulation matrix (GA), its structure,
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physicochemical properties, practical applications, and studies that utilizes GA alone or as a coencapsulant will be presented.
1.1 Vitamin D
1.1.1 Discovery, structure, source and physicochemical characteristics
Discovery of VD was credited to a select few individuals who made major contributions.
Alleviation of rickets like symptoms was first demonstrated by the work of Sir Edward Mellanby
in 1918 in feeding sunlight deprived dogs with cod liver oil (Holick 2003; DeLuca 2004).
However, it was the work of Adolf Windausin on elucidating the structure of several sterols
including VD3, and 7-dehydrocholesterol, the precursor of VD3 in the skin that earned him a Nobel
Prize in 1928 (DeLuca 2004).
Structurally, VD are secosteroids with a sterol structural resemblance to cholesterol (fourring core structure); however, unlike cholesterol, VD has a break between carbons 9 and 10 in the
B ring, with rings A, C, and D remaining intact (Gropper and others 2009). This break in C9-C10
bond is structurally important as it allows flexibility of the A-ring for rearrangement, resulting in
the synthesis of VD (Gropper 2009). This A-ring structure has been reported to play a significant
role in receptor binding, and the side-chain at C20 critical for metabolism (Boullata 2010). The
side-chain structure determines VD affinity for a transport protein referred to as, VD binding
protein (VDBP) (Gropper and others 2009). It is through the action of VDBP that transports VD
metabolites for tissue disposition (Gropper and others 2009).
There are two main dietary forms of VD (VD2 and VD3) that are structurally differentiated
by a double bond in C22 and C23 in VD2, and in VD3 a methyl group at C24 lacking (Boullata
2010). Natural VD dietary sources are either plant derived from irradiated ergosterol
(ergocalciferol, referred as VD2), or animal derived (cholecalciferol, referred as VD3) (IOM,
3

1997). Natural VD sources are limited and include, egg yolks, fish-liver oils, fatty fish, liver, and
mushrooms (Fixsen and Roscoe 1940; Mattila and others 1999; Nakamura and others 2002). VD
fortified foods include milk, margarine, cereal, and orange juice.
VD in foods is sensitive to light and oxygen which is attributed to the conjugated set of
double bonds in ring B (Gropper and others 2009). Luo and others (2012) demonstrated that when
non-encapsulated VD3 was exposed to 352 nm UV light, only 30% of the VD3 remains after 9.5
h. In a different study, when VD was packed under oxygen, only 10% of original potency remained
after four-week storage; whereas, 60% potency remained under nitrogen conditions (Fritz and
others 1942).
1.1.2 Biological functions
The major biological function of VD was previously isolated in its action with parathyroid
hormone (PTH) in the homeostasis of blood calcium concentrations and phosphorus metabolism
(Dusso and others 2005). However, there is increasing evidence of VD as an essential nutrient not
only for musculoskeletal health, but also in extra skeletal tissues (Jones and others 1998; Wang
and others 2010). For example, cell membrane receptors for VD are found in many tissues
including muscle, cardiac, pancreas (ß-cells), brain, and skin, thereby regulating various
physiological functions (Munker and others 1996; Holick 2004; Wang and others 2008; Cross and
Kallay 2009; Nazarian and others 2011; Roosens and others 2011; Morello and others 2018;
Abdel-Rehim and others 2019). Furthermore, there are growing evidences that show a multimodal
association linking circulating 25(OH)D levels in the blood with occurrence of diseases through
physiological functions (Goncalves and others 2014; Di Somma and others 2017; Hoseini and
others 2017; Zhang and others 2018b). The mechanism of disease development is complex and is
beyond the scope of our research. However, a simplified explanation may be attributed to VD role
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upon its activation by its cellular receptor, leading to transcription rates of target genes responsible
for biological responses (Li and others 1997; Dusso and others 2005; Ben-Dov and others 2007;
Abbas 2017).
VD is inactive until it undergoes two hydroxylation processes, first in the liver, and second,
in the kidney (Gropper and others 2009). In the liver, 25-hydroxylase functions at carbon 25 to
form 25-hydroxyvitamin D (also referred as 25(OH)D3, calcidiol or 25-OH cholecalciferol) which
represents the main form of VD released in the blood (Gropper and others 2009). The liver largely
secretes most of the 25(OH)D3 into the blood (largest single pool storage site) with little of this
metabolite taken up by the extrahepatic tissues (Gropper and others 2009). Most studies report
circulating 25(OH)D levels as a marker on VD status. The 25(OH)D level is correlated to oral VD
dosing from supplements and foods which is the first area of study because it precedes the
mechanism of action of VD in target tissues (Boullata 2010). When the body is deprived of VD,
release of VD from reservoirs including, skin and adipose tissue is taken up by tissues especially
the kidney (Gropper and others 2009). In the kidney, 1-hydroxylase functions to hydroxylate
25(OH)D3 at position 1, resulting in the second hydroxylation forming 1,25(OH)2D3 (also, referred
to as 1, 25 dihydroxy cholecalciferol, or calcitriol) (Gropper and others 2009). Calcitriol is
synthesized in the kidney due to action of NADPH-dependent enzyme (1-hydroxylase) which is
also present in various tissues (e.g., bone, intestine, skin, and macrophages) (Gropper and others
2009).
In order to understand why VD should be attained in sufficient levels, studies showing
what happens when the body lacks VD are briefly discussed. There are several studies that
demonstrated chronic implications resulting from decreased serum 25(OH)D. For example, 71.5%
(88/123) of elderly patients who are VD deficient (serum 25(OHD) < 12 ng mL-1) were associated
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with development of cognitive dysfunction (Zhang and others 2018b). In animal studies and
clinical trials there is an inverse correlation between low VD levels and increased diabetic
nephropathy (DN) (Nazarian and others 2011; Prietl and others 2013; Hu and others 2019).
Although VD3 is selected to be used in our study, it is important to mention why different
literature sources disagree on whether VD2 and VD3 have comparative efficacy or if one form is
superior than the other. The basis of selecting VD3 for our study will be explained by discussing
clinical trials that evaluated the efficacy of VD2 vs VD3. A randomized controlled trial of VD
replacement strategies comparing 50,000 IU of VD2 twice weekly for 8 weeks versus 50,000 IU
of VD3 given to children and young adults (6-21 yrs of age) with cystic fibrosis (CF) showed no
difference between groups in change of 25(OH)D (p = 0 .65), leading to the study conclusion that
both VD2 and VD3 are equally effective (Simoneau and others 2016). In contrast, participants
from an ambulatory osteoporosis clinic (≥ 18 yrs old) receiving 50,000 IU of VD3 or VD2 twice
weekly for 5 weeks showed VD3 to be more effective than VD2 in raising serum 25(OH)D levels
(+27.6 vs +12.2 ng mL-1) (Shieh and others 2016). Both studies have the same inclusion criterion
of serum 25(OH)D baseline (< 30 ng mL -1) (Shieh and others 2016; Simoneau and others 2016).
Human clinical trials have shown VD3 to be more effective than VD2 in treating nutritional VD
deficiency in demographics with chronic diseases (e.g., kidney disease, alcoholic liver cirrhosis)
(Malham and others 2012; Daroux and others 2013; Mangoo-Karim and others 2015; Tripkovic
and others 2017). Furthermore, comparison between VD3 versus VD2 fortification in animal feeds
(e.g., heifer) showed VD3 was more effective (e.g., increasing total beef VD content) than when
VD2 was used as a supplement (Duffy and others 2018).

6

1.1.3 Recommended dietary intake, status assessment, metabolism
There are various professional associations that provide level recommendations for VD
consumption. For example, the Institute of Medicine (IOM) is a regulatory authority that
determines the VD status and dietary recommendations of nutrients in North America (Fallon
2002). The IOM established the VD Recommended Dietary Allowance (RDA, covers ≥ 97.5 %
of the population) at 600 IU/d (ages 1-70 yr) and 800 IU/d (ages 71 and older) (Ross and others
2011). Professional associations have a consensus that serum 25(OH)D is the functional
indicator/biomarker of VD status and is expressed in units in ng mL-1 or nmol L-1. According to
the IOM, optimal levels for bone health which corresponds to 15-20 µg/d (1 IU cholecalciferol =
40 µg) meet serum 25(OH)D of at least 20 ng mL-1 (50 nmol L-1) (Ross and others 2011). The
Endocrine Society recommends a preferred 25(OH)D blood level range between 40-60 ng mL-1
(100-150 nmol L-1) (Holick 2017). Deficiency in VD is classified when 25(OH)D levels fall to
less than 20 ng mL-1 (50 nmol L-1) (Kim and others 2014).
Biochemical assessment to evaluate VD toxic status, in general, uses elevated calcium
levels as a marker. To date, no systematic VD intoxication levels have been studied in humans
due to ethical reasons (Jones 2008; Chakraborty and others 2015). Our understanding of VD
toxicity is from case reports that inadvertently over-fortified foods and/or error in prescription
recommendations. For example, over-fortified milk containing 70 to 600 times the recommended
2,000 IU VD gallon-1 resulted in patients (n = 56) having serum calcium level of 13.1 mg dL-1
exhibiting hypercalcemia symptoms (normal Ca levels = 9.8-10.8 mg dL-1) (Blank and others
1995); the 25(OH)D levels of these patients fit the laboratory determined minimum of 90 ng mL1

(225 nmol L-1) that is a default diagnosis of hypervitaminosis D. In a different study, a medication

error resulted in a female taking in VD3 supplementation of 60,000 IU once every day for a total
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of 4 mo alarmingly resulting in high 25(OH)D levels (746 ng mL-1 or 1,865 nmol L-1); however,
the elevated serum 25(OH)D levels did not result in elevated calcium levels and the woman
exhibited normal concentration of serum calcium (9.0 mg dL-1) (Chakraborty and others 2015).
The metabolism of VD in the body is also affected by amounts present in storage sites.
Combination of VD storage in adipose tissue and distribution mechanisms from liver and kidney
sites results in a slow turnover in the body (half-life ~2 mo) (Jones 2008). The main transported
metabolite, calcidiol (25(OH)D) has a half-life of ~15 d; whereas the hormone, calcitriol (1α,
25(OH)2D) has a half-life of ~15 h (Jones 2008). Calcitriol (from kidney) is the active form of
VD that targets tissues; however, calcidiol (from liver) reflects that largest indicator of circulating
VD in the blood (Gropper and others 2009). Calcitriol is “not suitable to assess vitamin D status
because it is kept within reference limits as long as possible by hormonal mechanisms, especially
parathyroid hormone (PTH) for stimulation and serum calcium and phosphate suppression” (Lips
2007). Therefore, serum 25(OH)D (calcidiol) is recognized as having direct effect on overall
nutritional VD status.
1.1.4 Tolerable upper intake level
The Food and Nutrition Board (FNB) established a tolerable upper intake level (UL) for
VD (50 μg d-1, or 2,000 IU) to mitigate the prevailing concerns of VD toxicity (Hathcock and
others 2007). VD supplementation dosage higher than the UL is reliable in raising serum 25(OH)D
without any toxicological symptoms or side-effects (Hollis and others 2012). This has been
demonstrated by clinical studies. For example, daily supplementation of 4000 IU VD3/day for 1
y to African American males was an effective strategy in raising serum levels > 40 ng mL-1 with
levels of 67.7 ng mL-1 after 1 y (Hollis and others 2012). In another study, no toxicological sideeffects were observed after a VD dose of 25,000 IU was given weekly to multiethnic obese children
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(8-14 yrs age), and these children’s 25(OH)D baseline when compared to 9 weeks later was at
adequate levels (< 50 to sufficiency > 50 nmol L-1) (Radhakishun and others 2014).
1.1.5 Challenges in food fortification
Natural sources of VD are limited and possibly infrequently consumed as evident in
nutrition surveillance data from various countries (Jayaratne and others 2013; Vaes and others
2017; Cashman and Kiely 2018). Furthermore, increasing reports of vitamin D insufficiency has
brought awareness on the need to consume more VD from the diet (Holick 2017; Jahn and others
2019).
It is important to take into consideration whether a product is appropriate to be fortified
with VD. The reason is that studies have found a link between perceived appropriateness of a
product being chosen to be fortified with VD with purchase intent (Jahn and others 2019). For
example, sausage or liver paté were considered inappropriate for VD fortification; whereas, milk
and cheese were considered neutral in appropriateness for fortification with VD (Jahn and others
2019).
As with any formulations, it is necessary to overcome several challenges. Practical
problems of adding small amounts of powdered forms of VD directly into foods is to accurately
measure and mix homogeneously with food. Liquid non-encapsulated VD are less of a problem
when added in fats and oils. However, VD, being lipid-soluble has limitations preventing its
compatibility with aqueous foods (e.g., beverages). Beverages are consumed regularly and is a
viable product for VD fortification because of its greater capacity to deliver the nutrient (Ahmad
and Ahmed 2019). VD needs to be encapsulated using water-soluble matrices that can entrap VD
for application in aqueous systems. Special considerations on VD load and type of coating material
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should provide easier dispersion throughout a product and yield to higher retention during
processing, storage and in vivo efficacy.
1.1.6 Encapsulated vitamin D for food or pharmaceutical use
Several delivery systems have been used to encapsulate VD. For example, ß-lactoglobulin
(ß-Lg), a protein found in whey was shown to successfully encapsulate VD3 by triggering the selfaggregation of the ß-Lg/VD3 coagulum by mild acidification (pH 4.7) with target applications in
dairy foods (e.g., cheese, yogurt) (Diarrassouba and others 2015b). The formulated ß-Lg/VD3
coagulum exhibited high encapsulation efficiency (EE) (94.5 ± 1.8%) and increased
photochemical stability to UV light (254 nm, 15 W) (94.2 ± 4.1% of the VD3 remained)
(Diarrassouba and others 2015b).
High amylose corn starch nanoparticle was used to encapsulate VD3 (EE range from 37.0678.11%) by means of ultrasonication (Hasanvand and others 2015). The VD3 loaded in high
amylose starch resulted in particle size dimensions < 40 nm, and food enrichment in milk showed
no difference in homogeneity from a blank control making it a promising carrier for VD3 in dairy
(Hasanvand and others 2015). The method of VD3 entrapment in amylose may be attributed to
the helical hydrophobic cavity which can be expanded upon alkali processing (Hasanvand and
others 2015). Additionally, VD3 loaded in high amylose is solubilized in aqueous systems due to
amorphous regions present in the polysaccharide chains and its relatively small size < 40 nm
(Hasanvand and others 2015). Other targeted delivery systems for VD3 formulation have included
stabilization of VD3 using emulsifiers (e.g., sodium caseinate; Tweens 20, 40, 60, 80, and 85;
soybean lecithin; decaglycerol monooleate; polysorbate 20 etc.) (Tippetts and others 2012; Guttoff
and others 2015; Tipchuwong and others 2017; Golfomitsou and others 2018; Shu and others
2018).

Nevertheless, expanding beyond dairy-based products for VD fortification may be
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beneficial due to high prevalence of lactose intolerance or milk sensitivity allergies (Casellas and
others 2016).
There are limited studies that aim to encapsulate VD3 for target applications in non-dairy
beverages. Some of these VD3 + matrix formulations include lipid-based carrier systems (e.g.,
nanoliposomes) (Mohammadi and others 2017), liprotides which are complexes of lipids and
partially denatured proteins (Pedersen and others 2016), soybean ß-conglycinin which is a globular
storage protein (Levinson and others 2014), and ß-cyclodextrin (Szejtli and Bolla 1980; Szejtli and
Tardy-Lengyel 1984; Delaurent and others 1998). Thus, further studies on improving VD3
stabilization/encapsulation in non-dairy beverages may be considered as it offers an alternative for
consumers.
1.1.7 Delivery and controlled release in vitro and in vivo studies
Maintenance of VD stability in the stomach and matrix release in the intestine are two
critical steps that precede the mechanism of its absorption over the membrane (Guan and others
2019). Therefore, a widely known prerequisite for effective absorption of VD is its solubilization
in the small intestinal fluids.
There are limited studies that evaluated the relationship between oral dose and absorption
of encapsulated VD3 in vivo. Entrapped VD3 in ß-lactoglobulin-lysozyme microspheres (EE =
90.8 ± 4.8%) fed to rats at a dose of 77 µg (3080 IU VD3) significantly increased the 25(OH)D
levels compared to rats fed non-encapsulated VD3 (42.4 ± 8.17 x103 and 15.12 ± 8.17 x103 nmol
L-1) (Diarrassouba and others 2015a). In human studies, VD3 in re-assembled casein micelles
resulted to comparable increase in serum 25(OH)D as that with VD3 in polysorbate-80
(PS80/Tween-80) (~ 8 ng mL-1) (Levinson and others 2016). Thus, research on release kinetics of
VD3 in other studies is needed if target health benefits are of importance.
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1.2 Gum arabic
1.2.1 Source and chemical structure
GA is a polysaccharide purified from natural exudate produced from various species of
Acacia senegal trees (Williams and Phillips 2009). The average molecular weight of GA has been
reported to be ~400,000 Da with a high degree of branching, spiral coils and polysaccharide side
chains (Ward 2000). GA in nature is primarily composed of mixed calcium, magnesium and
potassium salt of a polysaccharidic acid (arabic acid) (Glicksman 1983). GA has six carbohydrate
moieties which include the following: ᴅ-galactose (~44%), arabinopyranose and arabinofuranose
(~27%), L-rhamnose (~13%), ᴅ-glucuronic acid (~14.5%), and 4-O-methylglucuronic acid ~1.5%
(Glicksman 1983; Williams and Phillips 2009). Structural composition of GA is widely referred
to as an arabinogalactan-protein polysaccharide with fractions (as per total mass) being
arabinogalactan (~90%), arabinogalactan protein (~10%), and glycoproteins (~1%) (Randall and
others 1989).
The GA proteinaceous component gives it emulsifying functional characteristics (Williams
and others 1990). Major amino acid composition isolated in fractions primarily includes aspartic
acid, phenylalanine, serine, glutamic acid, glycine, valine, and leucine (Randall and others 1989).
In the whole gum, approximately 50% of its proteinaceous matter includes hydroxyproline (~41
nmol mg-1 gum,), serine (~22 nmol mg-1 gum) and proline residues (Randall and others 1989;
Phillips and others 2008).
GA solubility in water is attributed to its highly branched carbohydrate structure and
resembles a packed globular molecule. It exhibits low-viscosity in solutions even at relatively
high gum concentrations (Glicksman 1983; Islam and others 1997). For example, a 50% solution
of gum arabic has a similar viscosity to xanthan gum at 1.5% (Islam and others 1997). Other
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formulations from which GA was used with another compound (e.g., whey protein concentrate)
resulted in reduction of apparent viscosity values than other linear chain polysaccharides (e.g., 80250 times less than sodium alginate-whey protein concentrate) (Erben and others 2019).
1.2.2 Current food use and application
GA is widely used in the food industry to control and improve rheological properties of
food systems (Daoub and others 2018). The diversity of GA applications in food products includes
its actions as stabilizers, film formers, thickeners, emulsifiers, flocculants, and suspending agents
(Williams and others 1990; Ward 2000; Daoub and others 2018). For example, in the beverage
industry, GA is used in preparation of flavor emulsion concentrates (Tiss and others 2001). It is
also used as a “clouding” agent in dry beverage mixes (Glicksman 1983). Clouding agent is meant
to give aqueous solutions the turbid appearance of natural suspensions such as fruit juices or milk
(Wuhrmann and others 1975). Formulation in dry beverage products results in free-flowing
granules, and when reconstituted with water, gives the appearance and texture of fresh fruit juice
(Asano 2017). In soft drinks, brominated vegetable oils have been used as a “cloud” agent,
however, the use of GA to similarly mimic the effect have been proposed by Oppenheimer (1972).
Enrichment of non- or low-fat beverages utilizing GA as part of the formulation has
resulted in improved physicochemical properties in the target delivery food system. In beer, the
“lace curtain” effect on the sides of the glass upon beer consumption was achieved by using GA
as a foam stabilizer, demonstrated by Bavisotto and Hansen (1971). In confectionery, GA has
been used as a glaze or coating (imparts smoothness, flexibility, and pliability) because the gum is
cold-water soluble, forming clear solutions with viscosities approximately twice that of sugar
(Glicksman 1983).
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1.2.3 Carrier for labile compounds in food systems
Improvements in thermal stability of food bioactives using GA has been demonstrated by
multiple studies (Guan and Zhong 2015; Selig and others 2018; Zhang and others 2018a). In the
presence of GA, anthocyanins, a group of water-soluble pigments showed better protection from
thermal degradation after heating at 80 and 126 °C for 30 min, resulting in residual concentration
1.02 and 1.35 times higher than that without GA (Guan and Zhong 2015). Color stability of beet
extract processed under thermal treatment (50 and 80 °C) exhibited greater stability when
complexed with anionic polysaccharides, alginate and GA than with formulations without GA
(Selig and others 2018). Similarly, survival of Lactobacillus plantarum (LP) during isothermal
heating at 90 °C was strongly influenced by whether GA or reconstituted skim milk was used; with
GA alone as an encapsulant leading to the highest survival of LP cells (Zhang and others 2018a).
The abundant hydroxyl groups and branched structure of GA provide the fundamental basis on its
effectiveness in its strong adsorption properties (Kong and others 2014).
GA can stabilize bioactives across a wide pH range (pH > 2.0), which is particularly useful
in stabilization of pH sensitive ingredients added to highly acidic foods. For example, anthocyanin
pigments exhibit different chemical forms, which is dependent on the pH of the solution (Loypimai
and others 2016). Red color predominates at pH 1.0, quinoidal blue occurs when pH is between
2.0 - 4.0, and between pH 5.0 - 6.0, two colorless compounds (carbinol pseudobase and chalcone)
can be detected (Loypimai and others 2016). Guan and Zhong (2015) demonstrated that
incorporation of anthocyanins in GA significantly improved its stability not only in temperatures
up to 126 °C, but also at slightly acidic pH of 5.0. Similarly, ß-carotene protection at low pH was
shown to significantly improve upon encapsulation in bovine serum albumin and GA (pH 2.5 4.0) (Sheng and others 2018). Another example, tocopherol (TOC) encapsulated within zein-GA
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nanoparticles resulted in stable structures through a wide pH range between 3.0 and 9.0 (Li and
others 2018). The stability at a wide pH range improved upon addition of GA shows promising
applications to both acidic and neutral beverages.
1.2.4 Digestion and absorption
GA is not digestible in the upper gastrointestinal tract, and transit to the large intestine
results in slow fermentation by intestinal bacteria (Nasir and others 2008; Alarifi and others 2018).
Digestion of GA specifically increases Bifidobacterium spp and Lactobacillus spp. in healthy
subjects which is why GA is considered as a prebiotic and a natural dietary fiber (Alarifi and others
2018). Physiological-botanical description of dietary fibers is that of “remnants of plant
components that are resistant to hydrolysis by human alimentary enzymes” (Phillips and others
2008). Since GA is fermentable, its presence in the gut leads to production of beneficial short
chain fatty acids with fecal absorbability at around 95% (Mariod 2018). Thus, higher levels of
acetate, propionate, and butyrate that result from GA fermentation makes it a good prebiotic
(Alarifi and others 2018).
1.2.5 Delivery and controlled release
The use of GA as an emulsifier, encapsulating wall material, or as a co-ingredient in
formulations have demonstrated significant improvements in nutrient and/or bioactive absorption.
For example, in the study of Ozaki and others (2010), incorporation of coenzyme Q10 (CoQ10) in
GA by emulsification enhanced the CoQ10 bioavailability in rats and humans showing at least a 3fold increase when compared against non-emulsified GA with CoQ10 bulk formulation. In the
presence of GA, formation of mixed micelles is facilitated, and CoQ10 is solubilized reassembling
itself with chylomicrons. Lipophilic bioactives interaction with chylomicrons allows its uptake
within the enterocyte cells and transfer into the epithelium cells. Once this occurs, the bioactive
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lipophilic compound can be circulated through the portal vein and transported for metabolism in
the liver, resulting in enhanced bioavailability (Ozturk 2017).
In another study, GA as a co-encapsulating matrix with whey protein isolate (WPI) and
tuna oil (O) for a probiotic bacterium (L. casei) provided protection for the bacterium against acidic
pH conditions (pH=3.7) (Eratte and others 2015). The results of the study show that using GAWPI-O as a matrix significantly improved the viability of L. casei when compared to the control
regardless of whether L. casei were prepared as liquid suspension or spray dried, or freeze-dried
microcapsules. Eratte and others (2015) elucidated the importance of preventing the degradation
or inactivation of probiotics against acidic pH which may lead to a higher potential for desired site
delivery into the small intestines to receive any health promoting benefits.
The use of co-encapsulating matrices to protect probiotics may serve as a physical barrier
providing additional protection in gastric pH conditions. Protection of L. casei from gastric pH
conditions by using multiple encapsulating matrices including GA was previously demonstrated
by Gul (2017). The study showed that a combination of GA, maltodextrin, and reconstituted skim
milk resulted in more viable cell survival when compared with free cells after 60 min in simulated
gastric juices (pH 2.0). Viability of free cells were completely lost after processing at gastric pH
conditions, whereas, encapsulated L. casei had approximately 48 - 75% survival rate. Formulation
stability was further evaluated, and encapsulated L. casei resulted in 7-8 log cfu/g viable cell count
even after 21 d storage in refrigerated conditions. Thus, it is evident that incorporation of GA
either alone or as a co-encapsulant provides significant improvements in protection of otherwise
labile compounds.
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1.3 Concluding remarks
The use of GA in food systems shows a promising application in delivery of nutraceuticals
in beverages showing improved physicochemical and biological properties of bioactives as
discussed in preceding sections. Beverages are a good medium for delivery of nutraceuticals.
Addition of lipophilic vitamins in beverages will require dispersion and storage stability across a
wide pH range. Furthermore, encapsulated VD3 would have higher impact if evaluated using in
vitro and in vivo models to provide clinical relevance. This will allow us to understand the overall
bioavailability of encapsulated VD3 in GA and link potential health promoting effects as an added
ingredient in foods and/or beverages.
1.4 Hypothesis and overview of dissertation research
The overall hypothesis for this dissertation is that encapsulation of VD3 in GA will
facilitate the incorporation of VD3 in aqueous systems at a wide pH range and enhance
bioavailability. Specific objectives of the present dissertation are to (1) determine optimum
conditions of encapsulating VD3 in GA to maximize loading and characterize physicochemical
properties, (2) determine in vitro bioaccessibility of encapsulated VD3 in optimized formulation,
and (3) determine absorption of VD3 after a single high-dose (300 µg) and daily-dose (60 µg d-1
for 2-wks) oral supplementation by measuring 25(OH)D levels in Sprague-Dawley rats.
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Chapter 2 Encapsulation of vitamin D3 in gum arabic: physicochemical properties and
bioaccessibility
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2.1 Abstract
To incorporate lipophilic vitamin D (VD2 or VD3) in beverages, micro/nanoencapsulation
of VD in food biopolymers stable at a wide range of pH is a potential strategy. Gum arabic (GA),
a highly branched arabinogalactan with a conjugated peptide was evaluated as a potential VD3
carrier.

In this study, the two objectives were to (1) determine optimum conditions of

encapsulating VD3 in GA to maximize loading and characterize physicochemical properties, and
(2) determine in vitro bioaccessibility of encapsulated VD3 in optimized formulation. For 5% w/v
GA, encapsulation properties were evaluated for formulations with VD3 corresponding to 0.03,
0.06, 0.3, 0.6, 3.0, and 6.0% mass of GA. The encapsulation efficiency decreased while the loading
capacity increased with the increase in VD3 amount used in encapsulation. The treatment with
VD3 corresponding to 6% GA had the highest loading capacity (3.44%) and a satisfactory
encapsulation efficiency (71.35%) without visual phase separation and therefore was chosen for
further characterization. As pH increased from 2.0 to 7.4, the hydrodynamic diameter decreased
from 238.1 to 81.3 nm, the polydispersity index increased from 0.372 to 0.478, and the magnitude
of negative zeta potential increased from -3.1 to -31.0 mV. No precipitation was observed during
the 100-d storage at 3°C. Bioaccessibility of capsules was 95.76% and was significantly higher
than 68.98% of the non-encapsulated VD3. The capsules exhibited excellent stability at a wide pH
range and promise for delivery of VD3 in beverages.
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2.2 Introduction
Lipophilic vitamin D (VD2 or VD3) is widely known for maintaining bone health due to its
role in calcium and phosphorus homeostasis. Physiological needs of VD are fulfilled by photoconversion of VD in the skin through sunlight exposure or adequate dietary intake consumption at
15-20 µg d-1 (Del Valle and others 2011; Ross and others 2011). However, the average VD
consumption in U.S. has declined by ~ 5.3 µg capita-1 (NHANES 2009-2010), and diet sources are
receiving tremendous interest to overcome increasing reports of VD insufficiency (Calvo and
Whiting 2013; Jayaratne and others 2013; Dwyer and others 2014; Lopes and others 2014; Gomes
and others 2019).
To incorporate lipophilic VD in beverages, encapsulation of VD in colloidal particles is
needed. Dairy proteins are frequently investigated as a matrix for encapsulation of VD including
casein micelles or sodium caseinate (Markman and Livney 2012; Livney and Dalgleish 2015),
whey protein isolate (WPI) (Abbasi and others 2014) or individual whey proteins such as ßlactoglobulin (Diarrassouba and others 2015b) and α-lactalbumin (Delavari and others 2015).
Other researchers have added other materials as a co-encapsulant with dairy proteins. For example,
ß-lactoglobulin was investigated with co-encapsulating matrices of lactose (Gorska and others
2012), pectin (Zimet and Livney 2009), lysozyme (Diarrassouba and others 2015a), and ß-casein
(Forrest and others 2005). However, the use of dairy proteins has drawbacks such as the dispersion
instability at a pH close to the isoelectric point of proteins and allergenicity to certain consumers.
Other biopolymers investigated for VD encapsulation include chitosan (Rabelo and others 2018)
and its water-soluble derivative, carboxymethyl chitosan (Luo and others 2013) used alone or
crosslinked with other compounds e.g., zein or soy protein (Luo and others 2012; Teng and others
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2013). Chitosan is not soluble at neutral pH and is currently not approved as a generally recognized
as safe (GRAS) food additive in the USA (Kumar and others 2016).
In this study, Gum arabic (GA) was evaluated as a GRAS biopolymer for encapsulation of
VD3. GA is a water-soluble biopolymer widely used in the food industry (Garti and others 1993).
Functionality of GA in foods is attributed to its structure, which consists of arabinogalactanproteins (Akiyama and others 1984). The proteinaceous moiety of GA allows it to adsorb strongly
and effectively onto oil droplets (Garti and others 1993), and the adsorption of GA on oil droplet
surface results in the stability of oil-in-water emulsions at a wide pH range by means of repulsive
steric and electrostatic mechanisms (Garti and others 1993). The electrostatic force of GA is
attributed to the negative charge of carboxylate groups with pKa of 2.3 (Gulao and others 2016).
The amphiphilic nature of GA has been used to encapsulate and stabilize insoluble substances such
as natural colorants and tocopherols (Pitalua and others 2010; Khazaei and others 2014; Sanchez
and others 2015; Jian and others 2017). For example, GA improved the stability and solubility of
Monascus pigments (a natural colorant) in an acidic aqueous solution at pH 3.0-5.0 (Jian and others
2017). GA adsorbed on zein particles with encapsulated tocopherols improved the stability in a
wide pH range between 3.0 and 9.0 (Li and others 2018). However, GA alone has not been studied
for VD3 encapsulation.
We hypothesize that GA is a feasible biopolymer to encapsulate VD3 and the capsules have
physicochemical and bioaccessibility properties feasible for incorporation in beverages with a
wide range of pH. The specific objectives are to (1) encapsulate VD3 using gum arabic; (2)
evaluate physicochemical properties including storage stability of capsules; and (3) determine
bioaccessibility of VD3 in capsules after processing in simulated saliva, gastric, and intestinal
juices.
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2.3 Materials and methods
2.3.1 Materials
Cholecalciferol (VD3) crystalline powder (99% purity), Alfa Aesar™ was obtained from
Fisher Scientific (Pittsburgh, PA). GA powder, Pretested® Gum Arabic FT, was purchased from
TIC Gums (Belcamp, MD). HPLC grade solvents including water, hexane, methanol, butanol,
isooctane and ethanol were purchased from Sigma-Aldrich Corp. (St. Louis, MO).
Dimethylsulfoxide (DMSO) and reagents and chemicals of analytical grade were obtained from
either Fisher Scientific (Pittsburgh, PA) or Sigma-Aldrich Corp. (St. Louis, MO). Mucin, bovine
serum albumin, lipase, and pepsin were purchased from Sigma-Aldrich Corp. (St. Louis, MO).
2.3.2 Preparation of capsules
Encapsulation of VD3 was performed at room temperature (RT, 21 °C). GA solution was
prepared separately at 5% (w/v) in deionized water by blending at 9700 rpm for 4 min using a
shear homogenizer (Polytron® System PT 10-35 GT, Kinematica, Luzern, CH) and centrifugation
at 1912 g for 10 min (RC-5B centrifuge, SH-3000 rotor, Sorvall, DuPont, DE) to remove insoluble
particulates, and the supernatant was transferred into a 100-mL glass beaker. VD3 stock solution
was prepared by dissolving the VD3 powder in 5 mL ethanol (200 proof) at concentrations
corresponding to 0.03, 0.06, 0.3, 0.6, 3.0, and 6.0% mass of GA, named for Formulation I, II, II,
IV, V, and VI, respectively. After vortexing for 30 s, VD3 stock solution was added dropwise into
the GA solution while being blended at 8,000 rpm for 3 min using the above homogenizer. The
mixture was further homogenized at 10,000 rpm for 2 min before freeze-drying (Model Advantage
Plus EL-85, VirTis Company, Inc., Gardiner, NY). The freeze-dried powders were collected into
scintillation glass vials and stored at -20 °C in a freezer until analysis.
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2.3.3 Determination of total and non-bound vitamin D3 in freeze-dried powder
To quantitate the total amount of VD3 in unit mass of freeze-dried powder, 200, 30 and 10
mg of a freeze-dried powder sample was used for Formulations I and II, III and IV, and V and VI,
respectively. The powder was placed in a 50 mL test tube and mixed with solvents in a two-step
process. First, 5 mL of a binary solvent of DMSO and deionized water at a volume ratio of 9:1
was added, followed by heating at 60 °C for 10 min in a water-bath (model Reciprocal Shaking
Bath, Fisher Scientific, Winchester, VA). Samples were immediately cooled in an ice-bath, and
10 mL of isooctane was added, followed by stirring overnight at RT. Next, samples were
transferred to centrifuge tubes and 2 mL of deionized water was added to facilitate the separation
of DMSO and isooctane. Samples were left to stand at RT for 15 mins, and the mixtures were
centrifuged for 10 min at 1912 g (RC-5B centrifuge, SH-3000 rotor, Sorvall, DuPont, DE). The
supernatant was filtered using a polyvinylidene fluoride (0.45 μm) syringe membrane. The
permeate was used to quantify VD3 using Waters 2695 Series HPLC system (Waters Corp.,
Milford, MA, USA) equipped with a Waters 2998 model diode array detector set at 265 nm and
an injection valve with a 20-µL sample loop. The normal phase separation with a Waters
Spherisorb NH2 (5 µm, 4.6 x 150 mm) with guard column was conducted in isocratic mode at a
flow rate of 1 mL/min using a mobile phase composed of 98% isooctane, 1% butanol, and 1%
ethanol (Pastore and others 1997). Quantification was based on external standard (VD3 dissolved
in isooctane) with correlation coefficient of 0.999.
The amount of free VD3 was measured according to Luo and others (2012) with minor
modifications. Briefly, 130, 20, and 10 mg freeze-dried powdered was used for Formulations I
and II, III and IV, and V and VI, respectively. The powder was placed on a no. 1 Whatman filter
paper and flushed with 1 mL of hexane three times. The permeate was combined and dried using
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polytetrafluoroethylene Whatman syringe filter (Sigma-Aldrich Corp., St. Louis, MO, USA), the
permeate was analyzed with a Waters 2695 Series HPLC system (Waters Corp., Milford, MA,
USA) equipped with a Waters 2998 model diode array detector set at 265 nm and an injection
valve with a 20-µL sample loop. Compounds were separated on a reversed-phase Zorbax Eclipse
Plus C18 column (4.6 mm x 150 mm, 5 µm pore size) protected by Zorbax Eclipse Plus C18
analytical guard column (Agilent Technologies, Santa Clara, CA, USA). An isocratic methanol
mobile phase operating at a flow rate of 1 mL min-1 was used to elute VD3. Quantification was
based on an external standard (VD3 dissolved in methanol) with a correlation coefficient of 0.999.
2.3.4 Determination of encapsulation efficiency and loading capacity
The encapsulation efficiency (EE%) was calculated using Equation 1.
EE (%) = [1- (Free VD3 mass/Total VD3 mass used in encapsulation)] × 100 [1]
The loading capacity (LC%) was calculated based on total and free VD3 mass detected in
freeze-dried powder using Equation 2.
LC (%) = [(Total VD3 mass – free VD3 mass)/Total mass of freeze-dried powder)] x 100 [2]
2.3.5 Differential scanning calorimetry
Differential scanning calorimetry (DSC) of samples was performed using a Q2000
instrument (TA Instruments, New Castle, DE). A freeze-dried sample (2.0 ± 0.05 mg) was
weighed in an aluminum pan and sealed with a lid. An empty pan with lid was used as a reference.
Sample was equilibrated at 20 °C before a temperature ramp of 10 °C min-1 to 250 °C.
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2.3.6 Physicochemical properties of capsules and storage stability of reconstituted
dispersions
The physicochemical characteristics of fresh dispersion and the dispersion reconstituted
with freeze-dried sample of Formulation VI were characterized in comparison to a dispersion
rehydrated with freeze-dried powder prepared from the GA stock solution used in encapsulation.
The hydrodynamic diameter (Dh), polydispersity index (PDI), and zeta-potential were measured
using a model Zetasizer Nano ZS series instrument (Malvern Instruments, Ltd., Worcestershire,
UK). The dynamic light scattering (DLS) experiments were conducted at a scattering angle of
173°. The fresh dispersion was adjusted to pH 2.0-7.4 using 0.1 M NaOH or 0.1 M HCl. To
prepare reconstituted samples, a solution of 8 mM sodium phosphate dibasic solution with 0.01 %
sodium azide was prepared and pH adjusted to 2.0-7.4 using 0.1 M NaOH or 0.1 M HCl.
Subsequently, freeze-dried capsules and GA were hydrated in the phosphate buffer at a
concentration of 0.1 and 0.75 mg powder mass, respectively. All measurements were performed
in triplicate at RT.
To evaluate storage stability, dispersion reconstituted with freeze-dried powder containing
0.01% sodium azide were kept at 3°C in a refrigerator. The Dh, PDI, and zeta-potential were
measured periodically during storage for up to 100 days.
2.3.7 Assessment of bioaccessibility
Bioaccessibility of encapsulated VD3 in Formulation VI and free VD3 was evaluated.
Simulated saliva, gastric, and intestinal fluids (SF, GF, and IF, respectively) were prepared as
described in previous reports (Oomen and others 2003; Brandon and others 2006) with
modifications, outlined in Table 2.1. For the mouth phase, 6 mL of SF (pH 6.5 ± 0.2) was added
to freeze-dried capsules or free VD3 powder, followed by vortexing for 30 s and incubation at 37
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°C with continuous agitation (100 rpm) for 5 min. Second, 12 mL of GF was added, followed by
vortexing for 30 s and incubation at 37 °C with continuous agitation (100 rpm) for 2 h. Third, IF
represented as 12 mL of duodenal juice and 6 mL of bile juice was added with 2 mL sodium
bicarbonate (84.7 g L-1), followed by vortexing for 30 s and incubation at 37 °C with continuous
agitation (100 rpm) for 2 h. Lastly, to stop enzymatic activity, mixtures were incubated at 75 °C
for 20 min and immediately cooled using an ice-bath. Incubation with agitation of samples was
performed with a reciprocal shaking bath (Fisher Scientific, Winchester, VA).
After simulated digestions, mixtures were centrifuged at 26,892 g for 30 min (fixed angle
SS-34-10.70, Sorvall, DuPont, DE) to collect the micelle phase (supernatant). In preliminary
experiments, VD3 in the micelle phase was not quantifiable using the above HPLC conditions,
likely below the detection limit. Instead, the precipitate in the centrifuge flask was stored in -40
°C overnight and freeze-dried. The centrifuge flask was directly added with 5 mL of binary solvent
with DMSO and deionized water at a volume ratio of 9:1, followed by heating at 60 °C for 10 min
in a reciprocal shaking bath (Fisher Scientific, Winchester, VA). After immediate cooling in an
ice-bath, 10 mL of isooctane was added, followed by stirring using magnetic stir plate overnight
at RT. Next, samples were transferred to centrifuge tubes and 2 mL of deionized water was added
to facilitate the separation of DMSO and isooctane. Samples were left to stand at RT for 15 min,
and the mixtures were centrifuged for 10 min at 1912 g (RC-5B centrifuge, SH-3000 rotor, Sorvall,
DuPont, DE). The supernatant was filtered using polyvinylidene fluoride (0.45 μm) membrane
filter prior to quantification using normal phase HPLC as described previously.
2.3.8 Data and statistical analysis
All experiments were conducted in triplicate with data reported as the mean ± standard
deviation (SD). Statistical analysis was performed using SPSS v.25 for Windows software
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(Chicago, IL) or SAS 9.4 for Windows 64x from SAS Institute. (Cary, NC). The significance level
was set at a p value of 0.05. Analysis of the differences between treatments was performed using
two-way ANOVA with Tukey’s multiple-comparison test.
2.4 Results and discussion
2.4.1 Encapsulation properties
Table 2.2 delineates total VD3, and free/unbound VD3 in freeze-dried powder that were
used to determine EE and LC (Table 2.3). As the amount of VD3 used in encapsulation increased,
a decline in EE (99.45 to 71.35%) and an increase in LC (0.02 to 3.44%) were observed. As GA
has a small fraction (1.5-2.6%) of proteins (Idris and others 1998) to provide binding for VD3, a
decrease in EE and an increase in the amount of VD3 extractable by hexane washing is expected.
Our results are comparable to some studies. VD3 encapsulated in zein nanoparticles coated
with carboxymethyl chitosan had an EE of 87.9 % and an LC of 2.1 % (Luo and others 2012).
This same research group added soy protein isolate as a co-encapsulant with carboxymethyl
chitosan to protect VD3 which resulted in an EE of 84.46% and an LC of 6.06% (Teng and others
2013). Other matrices used to encapsulate VD3 were reported for much higher EE, including fish
oil (EE% = 96.95%) (Walia and others 2017), nanoliposomes (EE% = 93%) (Mohammadi and
others 2017), niosomes (EE% = 95.9%) (Wagner and others 2016), and carboxymethyl chitosan
beads (EE% = 96.9%) (Luo and others 2013). However, drawbacks using these matrices include
the incompatibility with acid-based beverage systems, turbidity, and suitability and label
friendliness for beverage applications.
Figure 2.1 shows the thermal properties from DSC analysis of non-encapsulated VD3 and
GA with corresponding melting point of 81.4 and 160 °C, respectively. The DSC thermogram of
VD3 is in agreement with Tsai and others (2017). The thermograms of freeze-dried powder
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produced with 6 formulations of different VD3-GA amounts are shown in Figure 2.2. All 6
formulations showed a disappearance of the VD3 melting point with only the GA melting point
observed at 160 °C which suggest an inclusion complex was formed.
Although the formulation VI had the lowest EE, it had the highest VD3 LC and had
characteristics for beverage applications, as presented below. The high LC provides convenience
in sample preparation when a relatively large amount of VD3 is needed, e.g., for animal feeding
studies. Therefore, this formulation was characterized for physicochemical properties and
bioaccessibility.
2.4.2 Physicochemical properties of capsules before and after freeze-drying
The Dh is shown in Figure 2.3 for fresh dispersions and 1 h after reconstituting with
capsules or GA at pH 2.0-7.4. The Dh was independent on pH (p > 0.05). The fresh dispersion
had smaller Dh (276.6 nm) than the reconstituted capsule dispersion (304.1 nm), which suggests
incomplete hydration of capsules in less than 1 h. The bigger Dh of fresh and reconstituted capsule
dispersions than that of GA (38.8 nm) suggests the encapsulation of VD3 increased particle
dimension. The incomplete hydration of freeze-dried powder was also indicated by the relatively
large PDI of capsules and GA (Figure 2.4), indicating heterogeneity in particle size distribution
(Navideh and others 2012). The PDI range of capsules observed in our study is comparable to the
PDI of astaxanthin stabilized by GA (Navideh and others 2012).
The zeta-potential is shown in Figure 2.5. The zeta-potential measurements for all 3
samples was negative over the pH range studied (2.0 – 7.4) and had a bigger magnitude at a higher
pH. This is primarily attributed to the ionizable side chain carboxylate group of the GA molecule
(Islam and others 1997; Weinbreck and others 2003). Both pH and ionic strength of solutions
influence stability of capsules dispersed in solutions (Weinbreck and others 2003). Addition of
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acid lowers the surface charge of the GA molecule due to protonation of carboxylate groups
resulting in a decrease in electrostatic repulsion between particles (Liu and others 2010).
Increasing the ionic concentration of dispersions screens charges and weakens electrostatic
repulsion, leading to aggregation of particles (Ozturk and others 2015; Zha and others 2019).
Therefore, a balance between pH and ionic strength of solution needs to be maintained for capsule
stability. In our study, the zeta-potential magnitude is small at low pH values, but no precipitation
was observed. This is attributed to both electrostatic repulsion and steric hindrance resulting from
polysaccharide chains of GA on particle surface preventing particle aggregation (Liu and others
2010; Guan and Zhong 2015; Zha and others 2019).
2.4.3 Physicochemical properties during 100 d storage at 3 °C
The GA control had a consistent Dh of 39 nm at pH 2.0 to 7.4 throughout 100 d storage
(Figure 2.6), which is in good agreement with other studies (Abdolkhalegh and others 2018; Lv
and others 2019). The larger errors on Dh day 0 than later days, e.g., day 20, suggest freeze-dried
powder was continuously hydrated during storage. On the same day, the Dh overall decreased as
the pH was increased, which was most evident on day 100 showing Dh of 238.1 nm and 81.3 nm
at pH 2.0 and 7.4, respectively.
The bigger PDI of capsules at a higher pH suggested the more polydispersed systems as
pH increased (Figure 2.7). For example, the PDI was 0.649 and 0.376 at a pH of 7.4 and 2.0,
respectively. The magnitude of zeta-potential of capsules increased from absolute -3.09 to -40.58
mV as pH increased from 2.0 to 7.4 during the 100-d storage (Figure 2.8). For all treatments, no
precipitation was observed throughout the storage, and particle aggregation was not apparent
(Figure 2.6). It is widely accepted that stable emulsions exhibit a zeta-potential magnitude greater
than 25 mV (Lamba and others 2015). As discussed previously, the stability of capsule dispersions
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during storage is similarly attributed to repulsive electrostatic and steric forces originating from
GA molecules (Zhang and others 2015; Ozturk 2017).
2.4.4 Bioaccessibility of vitamin D3 encapsulated in gum arabic
The amount of VD3 that was bioaccessible after processing in simulated saliva, gastric, and
intestinal juices was indirectly measured by evaluating the precipitate instead of the micelle
portion. Processing of the micelle portion would require freeze-drying ~48 mL of digestive juices
prior to quantification using HPLC. The higher volume resulted to more sample loss after freezedrying due to transfer of contents for the multi-step extraction process. The loss was attributed to
the dried-up micelles which adheres to the container walls, making it difficult to effectively
transfer contents without significant sample loss. Therefore, it was more feasible to freeze-dry the
precipitate instead of the micelle portion to prevent sample loss. Furthermore, solvent extraction
using the binary solvent composed of DMSO and water at a 9:1 ratio was more effective in
extracting VD3 from the precipitate because the sample mass of the precipitate was significantly
less than that of the micelle portion.
In Table 2.4, the VD3 recovered from the precipitate of capsules after simulated digestions
was significantly less than that of the non-encapsulated VD3 (4.2 and 31.0%, respectively). Thus,
it is possible, that 95.8% of VD3 in capsules would have been bioaccessible, in contrast to only
69% in the non-encapsulated form. The results suggest VD3 encapsulated in GA may have a
significantly higher bioavailability after digestion, which is to be validated in vivo.
2.5 Conclusions
In this study, we successfully encapsulated VD3 using GA as an encapsulation matrix. At
chosen conditions, a high LC of 3.44% and a moderate EE of 71.35% were observed. These
capsules exhibited good stability across a pH range between 2.0 and 7.4, attributed to a generally
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small Dh and molecular characteristics of GA providing strong repulsive forces preventing particle
aggregation during 100-d refrigerated storage. The higher bioaccessibility of encapsulated VD3 in
GA than the non-encapsulated form further suggests the benefit of encapsulation. Overall, the
studied encapsulation system holds great potential as a value-added ingredient to supplement
lipophilic VD3 in beverages with a wide pH range.
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Appendix
Table 2.1. Compositions of simulated saliva and gastrointestinal juices adapted from Brandon and others (2006) and Oomen and others
(2003).
Saliva juice

Gastric juice

Duodenal juice

Bile juice

2,752 ± 14 mg NaCl
266 ± 3 mg NaH2PO4
824 ± 8 mg KCl
400 ± 4 mg CaCl2.2H2O
306 ± 4 mg NH4Cl
6.5 mL 37% HCl

7,012 ± 35 mg NaCl
3,388 ± 17 mg NaHCO3
80 ± 4 mg KH2PO4
564 ± 6 mg KCl
50 ± 5 mg MgCl2.6H2O
180 µL 37% HCl

5,259 ± 26 mg NaCl
5785 ± 29 mg NaHCO3
376 ± 4 mg KCl
150 µL 37% HCl

Inorganic phase (500 mL)
896 ± 4 mg KCl
200 ± 4 mg KSCN
888 ± 4 mg NaH2PO4
570 ± 6 mg Na2SO4
298 ± 3 mg NaCl
1,694 ± 8 mg NaHCO3
Organic phase (500 mL)
200 ± 2 mg urea

650 ± 7 mg glucose
100 ± 5 mg urea
250 ± 2.5 mg urea
20 ± 2 mg glucuronic acid
85 ± 1.5 mg urea
330 ± 3 mg glucosamine HCl
Combine organic and inorganic phase in corresponding digestive juices and add the following components:
290 ± 3 mg amylase
15 ± 1.5 mg uric acid
25 ± 2 mg mucin

1 ± 0.005 g BSA
2 ± 0.13 g pepsin
3 ± 0.015 g mucin

200 ± 4 mg CaCl2.2H2O
1 ± 0.005 g BSA
9 ± 0.045 g pancreatin
1.5 ± 0.0075 g lipase

222 ± 2 mg CaCl2.2H2O
1.8 ± 0.009 g BSA
30 ± 0.03 g bile

8.1 ± 0.1

8.2 ± 0.1

pHa
a

6.8 ± 0.1
1.3 ± 0.1
Adjust pH with 1.0 M NaOH or 37% HCl.
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Table 2.2. Total and free vitamin D3 in freeze-dried powder. *
Formulation

Mass% of VD3 with respect to VD3% with respect to total mass used in encapsulation
gum arabic
Total detected
Free/unbound

Control

Non-encapsulated
vitamin D3

98.1 ± 7.16ab

I

0.03

81.7 ± 0.26bc

0.9 ± 0.17b

II

0.06

88.3 ± 0.42b

0.5 ± 0.10b

III

0.3

95.6 ± 0.52ab

0.7 ± 0.12b

IV

0.6

93.5 ± 1.62ab

4.3 ± 0.23b

V

3.0

83.4 ± 1.45bc

20.8 ± 3.13a

VI

6.0

78.3 ± 2.95c

25.9 ± 10.85a

*

Different superscript letters show significant difference within the column based on two-way ANOVA (P < 0.05).
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Table 2.3. Encapsulation efficiency (EE%) and loading capacity (LC%) of treatments with VD3 used at 0.03-6.00 % of mass of gum
arabic (GA).*
Formulation

VD3 amount in mass% of GA

EE%

LC%

I

0.03

99.45 ± 0.11 a

0.02 ±0.00 d

II

0.06

99.65 ± 0.06 a

0.05 ±0.00 d

III

0.30

99.75 ± 0.04 a

0.29 ±0.00 cd

IV

0.60

98.53 ± 0.07 a

0.55 ± 0.01 c

V

3.00

86.62 ± 6.40 b

2.29 ± 0.05 b

VI

6.00

71.35 ± 5.84 c

3.44 ± 0.38 a

*Mean ± SD. Different letters represent significant difference within the column (P < 0.05).
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A)

81.4 °C
Vitamin D3
Melting
Point

B)

160 °C
Gum Arabic
Melting Point

Figure 2.1. Differential scanning calorimetry (DSC) thermograms of A) non-encapsulated VD3, and B) gum arabic.
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A)

D)

81.4 °C Melting Point
Non-observed (A to F)

160 °C
Melting Point
(A to F)

B)

E)

C)

F)

Figure 2.2. DSC thermograms of capsules prepared with VD3 at A) 0.03, B) 0.06, C) 0.3, D) 0.6, E) 3.0, and F) 6.0% mass of gum
arabic.
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Figure 2.3. Mean hydrodynamic diameter (Dh) of fresh dispersion with VD3 corresponding to 6% mass of gum arabic, dispersion
reconstituted with the corresponding freeze-dried powder, and gum arabic at pH 2.0-7.4. Error bars are SD (n=3). Different letters
above bars indicate statistical difference among samples at the same pH (P < 0.05).
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Figure 2.4. Polydispersity index (PDI) of fresh dispersion with VD3 corresponding to 6% mass of gum arabic, dispersion reconstituted
with the corresponding freeze-dried powder, and gum arabic at pH 2.0-7.4. Error bars are SD (n=3). Different letters above bars indicate
statistical difference among samples at the same pH (P < 0.05).
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Figure 2.5. Zeta potential of fresh dispersion with VD3 corresponding to 6% mass of gum arabic, dispersion with the corresponding
freeze-dried powder, and gum arabic at pH 2.0-7.4. Error bars are SD (n=3).
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A)

B)

Figure 2.6. Mean hydrodynamic diameter (Dh) of A) gum arabic, and B) dispersion reconstituted with freeze-dried powder prepared
with VD3 corresponding to 6% mass of gum arabic during 100-day storage at 3 °C. Error bars are SD (n=3).
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A)

B)

Figure 2.7. Polydispersity index (PDI) of A) gum arabic, and B) dispersion reconstituted with freeze-dried powder prepared with VD3
corresponding to 6% mass of gum arabic during 100-day storage at 3 °C. Error bars are SD (n=3).
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A)

B)

Figure 2.8. Zeta-potential of A) gum arabic, and B) dispersion reconstituted with freeze-dried powder prepared with VD3 corresponding
to 6% mass of gum arabic during 100-day storage at 3 °C. Error bars are SD (n=3).
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Table 2.4. Vitamin D3 detected in the precipitate after simulated mouth, gastric and intestinal phase digestions.
Sample

Vitamin D3 recovered in precipitate (%)*

Non-encapsulated vitamin D3

31.0 ± 0.8a

Capsules prepared with vitamin D3 at 6% mass of gum arabic

4.2 ± 0.4b

* Different superscript letters indicate significant differences at P < 0.05.
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Chapter 3 Encapsulation of vitamin D3 in gum arabic: in vivo bioavailability in SpragueDawley rats
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3.2 Abstract
Vitamin D3 (VD3) is a lipophilic hormone precursor and improving its incorporation in
water by encapsulation in colloidal particles may address its nutritional significance for VD3
deficient consumers. The aim of this study was to evaluate the efficacy of an encapsulation system
previously developed in enhancing the bioavailability of VD3. We hypothesize that encapsulation
in gum arabic (GA) will improve the absorption of VD3 when compared to unencapsulated VD3.
The objective was to determine absorption of VD3 after a single high-dose (300 µg) and daily-dose
(60 µg/d for 2-wks) oral supplementation by measuring 25(OH)D levels in Sprague-Dawley rats.
The rats at weaning age were randomly assigned to one of 6 groups (n=10/group, 60 rats total,
male and female equally distributed). Rats received either a vitamin D sufficient (VDS) (2200
IU/kg diet) or a vitamin D deficient (VDD) (0 IU/kg diet) pellet food and water ad libitum. The
two control groups were in a VDS or a VDD group given an oral gavage of GA alone. The four
treatment groups included rats fed with a VDD diet and gavaged with non-encapsulated VD3, a
physical mixture of GA and VD3, or encapsulated VD3, and rats fed with a VDS and gavaged with
encapsulated VD3. The 25(OH)D level in serum was determined by competitive enzyme-linked
immunosorbent assay. The in vivo pharmacokinetic study results after oral gavage of 300 µg VD3
showed that the serum 25(OH)D level area-under-curve in 48 h of the encapsulation treatment was
4.32-fold of the non-encapsulated VD3 and more than twice higher than the treatment with simple
mixture of GA and VD3. At 2-wks after the oral gavage of 60 µg VD3/d, rats that received capsules
or physical mixture had 25(OH)D levels that were at least 81 ng mL-1 higher than that of the nonencapsulated VD3 group. The results of this study show encapsulating VD3 in GA is an effective
strategy to improve absorption of lipophilic VD3.
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3.3 Introduction
Foods enriched and/or fortified with vitamin D (VD) e.g., milk, orange juice, margarine,
and cereal contribute to a proportion of VD intake; but food choice patterns influence whether
people can get adequate VD (Dwyer and others 2014). Consequently, recommended levels of
Adequate Intake (AI) of VD for adults at 600 – 800 IU/day or 15 – 20 µg/day is not being met
resulting to decreased levels of serum 25-hydroxyvitamin D [25(OH)D], also known as calcidiol,
a status biomarker (Holick and Chen 2008; Holick 2017). Therefore, there is a desired need to
obtain nutrients from fortified food products, and for busy, on-the go consumers a continued
demand for convenient foods (Zimet and Livney 2009; Casey and others 2018). A potential
strategy is to encapsulate VD in a food grade water-soluble matrix to increase its solubilization in
aqueous foods. Furthermore, encapsulated VD must be stable against gastric pH degradation
(Cohen and others 2017) for target delivery in the small intestines where VD is absorbed.
Determining oral VD uptake by pharmacokinetic and daily dose studies are linked to
uptake and retention in target tissues (Chow and others 2013; Apaydin and others 2018; Neme and
others 2018). Oral administration of encapsulated VD is evaluated by assessing serum 25(OH)D
levels because it represents the best indicator of VD status not only from food, but also from
supplements or endogenous production of VD from sunlight (Norman 2008). There are limited
studies that systematically assessed efficacy of encapsulated VD in vivo in animal (Diarrassouba
and others 2015) or human subject (Levinson and others 2016). In Wistar rats, VD3 prepared with
bovine ß-lactoglobulin (ß-Lg) with a final VD3 concentration of 77 µg (3080 IU/d) (1 IU
cholecalciferol = 40 µg) as a coagulum was administered every day for 3-wks via oral gavage
(Diarrassouba and others 2015). After 3-wks, VD3 in the mixture was better absorbed when
compared with non-encapsulated VD3 (42.4 vs. 15.1 µM serum 25(OH)D) (Diarrassouba and
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others 2015). In humans, bioavailability of 1,250 µg or 50,000 IU encapsulated VD3 in reassembled casein micelles (VD3- rCMS) and/or in polysorbate-80 (PS80/Tween-80) (VD3-PS80),
a commonly used synthetic emulsifier, was evaluated in fat-free yogurt and compared against a
control group receiving a VD3-free placebo control (Levinson and others 2016). Results showed
mean serum ∆25(OH)D levels increased similarly (~8 ng ml-1) for both VD3- rCMS and VD3-PS80
against the VD3-free placebo group (Levinson and others 2016). Nevertheless, the encapsulated
VD3 ingredients (Diarrassouba and others 2015; Levinson and others 2016) are targeted for
applications in semi-solid foods e.g., cheese, yogurt due to rheological impact on final product
e.g., increase in viscosity and elasticity. Therefore, improvements in VD3 encapsulation for
delivery in other food systems with enhanced bioavailability are needed.
Gum arabic (GA) may be used as a potential VD3 carrier in food systems. GA is a
hydrocolloid derived from exudates of Acacia senegal or Acacia seyal trees widely used in the
food and pharmaceutical industry as an emulsifier and stabilizer (Nasir and others 2008; Phillips
and others 2008). GA as an emulsifier has both hydrophilic and lipophilic portions which promote
the mixing of lipids in water (Rolfes and others 2014) which may facilitate the incorporation of
VD in aqueous systems. Emulsification of fats with bile is an important step that precedes
absorption. Bile which is stored in the gallbladder is not an enzyme but contains emulsifiers that
brings lipids into suspension in water to facilitate enzymes (pancreatic and intestinal lipases) to
hydrolyze tri- and di- acylglycerols (Rolfes and others 2014). These hydrolyzed lipids dissolving
lipophilic nutrients will then be absorbed within the small intestinal wall (Insel and Wardlaw 1996;
Gropper 2009). These nutrients then undergo transport via vessels that merge into the portal vein,
which conducts all absorbed materials into the liver (Insel and Wardlaw 1996; Gropper 2009).
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GA alone and/or used as a co-encapsulant with another matrix increased the bioavailability
of lipophilic compounds (Zhou and others 2018). For example, droplets with esterified astaxanthin
emulsified within whey protein/GA showed significantly higher concentrations of astaxanthin in
plasma with a peak at 9 h (tmax) after ingestion when compared with esterified astaxanthin oleoresin
(control) with a tmax of 12 h (Zhou and others 2018). Similarly, encapsulation of co-enzyme Q10
(CoQ10) with GA significantly improved its bioavailability when compared to non-emulsified
CoQ10 bulk powder (Ozaki and others 2010). Specifically, oral administration of emulsified CoQ10
showed significantly greater serum and/or plasma CoQ10 levels with tmax of 2 and 6 h for rats and
humans, respectively; whereas, the CoQ10 bulk powder control showed the absence of peak in
serum and/or plasma CoQ10 levels (Ozaki and others 2010). GA has also been studied as a wall
material to protect lipophilic nutraceuticals e.g., ß-carotene, lycopene, and lutein and improve
physicochemical properties (Montenegro and others 2007; Qv and others 2011; Boiero and others
2014); however, bioavailability via in vivo studies was not assessed in these studies.
In Chapter 2, VD3 was incorporated successfully in GA as particulates with a
hydrodynamic diameter (Dh) of 242.54 nm, and particles remained dispersed in a wide pH range
between 2.0 to 7.4 during 100-day storage at 3 °C. Additionally, bioaccessibility of VD3 after
simulated mouth, gastric and intestinal phase digestions showed that 95.81% of encapsulated VD3
could be potentially absorbed, which was significantly higher than 68.98% of non-encapsulated
VD3. These preliminary studies suggest the feasibility of the studied food grade capsules to
enhance VD3 bioavailability with promising applications in beverage systems.
Our research hypothesis is that encapsulation of VD3 in GA will enhance absorption of
VD3. The objective is to investigate the bioavailability of VD3 encapsulated in GA using SpragueDawley rats after a single high-dose of 300 µg and a two-week daily lower dose of 60 µg/day.
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This study marks the first in vivo investigation into the oral delivery performance of VD3
encapsulated in GA.
3.4 Materials and methods
3.4.1 Materials
Cholecalciferol, VD3, crystalline powder (99% purity), Alfa Aesar™ was obtained from
Fisher Scientific (Pittsburgh, PA). TIC Pretested® Gum Arabic FT Powder was purchased from
TIC Gums (Belcamp, MD). Propylene glycol (99.9% pure USP Food Grade) was sourced from
Amazon (Froggys Fog brand). Sodium phosphate dibasic and citric acid were obtained from
Sigma-Aldrich Corp. (St. Louis, MO). Isoflurane was provided by the Institutional Animal Care
and Use Committee at the University of Tennessee, Knoxville (UTK-IACUC) for use in animal
study. The 2% chlorhexidine antiseptic solution sourced from a local veterinary clinic was used
to wipe tail of rats to prevent infection and to clean the wound after blood withdrawal. Sucrose
was obtained from a local grocery store.
3.4.2 Animals and diets
All procedures were approved by the UTK-IACUC (protocol numbers: 2123 and 2547).
Treatments of animals were in accordance with the Guide to the Care and Use of Experimental
Animals. For protocol# 2123, three female and two male Sprague-Dawley (SD) rats (7 weeks of
age) were purchased from Envigo (Envigo, Indianapolis, IN) and used for breeding. The SD rats
underwent a one-week acclimation period. After acclimation, one male and no more than 2 female
rats were grouped per breeding cage. Environmental conditions in the animal facility had an
average daily temperature of 21 ± 3 °C, and humidity range of 45-65%, and 12 h of light alternating
with 12 h of darkness. Cages were maintained and cleaned twice a week and placed with an
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enrichment (PVC pipe or a paper cone). For the entire duration of the study, all SD rats were
housed in colony cages with bedding and were given food and demineralized water ad libitum.
Breeding pairs were fed with Teklad rodent chow (#8640, Harlan Laboratories, Indianapolis, IN)
which supports normal growth and reproduction in laboratory rodents. Males used for breeding
were separated from the cage when females delivered new pups. Pups were weaned at Day 21 and
transferred to protocol 2547 at 4 wks old.
In protocol# 2547, a total of 60 SD rats (30 male, 30 female) were obtained from the
original SD breeding pairs. Each SD rat was randomly distributed into one of 6 groups (N=10 per
group, 5 males and 5 females). Figure 3.1 delineates the overall general schematic of the in vivo
study design. SD rats first underwent an 8-wk dietary manipulation. Weaned male and female
SD rats were assigned to groups to receive either a VD sufficient (VDS) (TD.96348, 2200 IU
Vitamin D/kg diet) (Table 3.1) or a VD deficient (TD.87095, 0 IU Vitamin D/kg diet) (Table 3.2)
pelleted food. Both VDS and VDD diets contained 20% lactose, 2.0% calcium, and 1.25%
phosphorus.
The duration of 8 weeks has been shown to be the length of time needed to successfully
induce VDD in rats (Warner and Tenenhouse 1985; Benbrahim and others 1988) or mice (Kankova
and others 1991; Malley and others 2009). Experiments began when the rats reached 12-wks of
age.
3.4.3 Preparation of treatments for gavage administration in phase I and phase II
All formulations administered on Day 78 for Phase I pharmacokinetics study are outlined
in Table 3.3. For the animals receiving capsules, the following procedures of sample preparation
were performed. First, GA solution was prepared at 5% (w/v) in deionized water. Second, VD3
solutions was prepared separately in 5 mL ethanol corresponding to 6.0% mass of GA. Mixtures
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of both components involved dropwise addition of the VD3 solution into 50 mL GA solution while
blending at 8,000 rpm for 3 min, then, 10,000 rpm for 2 min before freeze-drying. This formulation
represents the capsules used for delivery in treatment 3 (VDS- Capsules, T3), and treatment 4
(VDD- Capsules, T4). Preparation of test solutions containing these capsules for oral gavage
administration first required creating a stock solution containing 8 mM sodium phosphate dibasic
(food-grade) adjusted to pH 7.0 using 0.1 M citric acid. For the single high-dose gavage samples
used for pharmacokinetics, a target of 1 mL gavage volume containing 300 µg of VD3 present in
the capsules was needed. The actual VD3 amount detected in freeze-dried powder (52.1 µg
VD3/mg powder), as presented in Chapter 2, was used to determine mass of capsules needed to
deliver 300 µg VD3.
Non-encapsulated VD3 (T1) was prepared by dissolving VD3 in propylene glycol before
being added to the phosphate buffer at pH 7.0. The physical mixture treatment (T4) consisted of
both non-encapsulated VD3 and GA prepared by mixing the non-encapsulated VD3 dissolved in
propylene glycol and GA dissolved in the phosphate buffer at concentrations equivalent to the
capsule treatment. Lastly, the controls (C1 and C2) consisted of GA alone prepared by dissolving
GA in the phosphate buffer at a level comparable to the capsule treatment.
All formulations administered during phase II, with target daily dose amount of 60 µg/d
for two-week period, are delineated in Table 3.4. Samples were dissolved similarly to those in
Phase I, except with different masses of compounds.
Test liquid dispersions were orally administered using a gavage needle, Type 304 (SS-304)
curved 3-in stainless-steel feeding tube with a stainless-steel ball at the tip. To reduce stress on
the animal, the rats were acclimatized by allowing them to lick a precoated/dipped sugary solution
(≤ 1 g mL-1) up to two weeks prior to the first gavage treatment. On treatment days, the tip of the
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gavage needle was precoated/dipped in a sugary solution (≤ 1 g mL-1) prior to gavaging rats with
test liquid dispersions. A general schematic on how the formulations were administered to the rat
is shown in Figure 3.2. Briefly, a treatment solution was placed in a syringe attached to the 3-in
stainless-steel feeding tube and contents released slowly while positioned at the last rib cage for
direct delivery in the stomach.
3.4.4 Blood collection and serum separation
Blood withdrawal from the rat in the lateral tail vein was performed with a surflo winged
infusion butterfly catheter (25 g x ¾”) equipped with a tube (Lee and Goosens 2015). The rat was
first anesthetized using isoflurane in an open drop method. The rats were restrained using a conical
decapicone or a rodent restrainer (max < 10 min), and the rat tail was placed in water at 41 ± 2 °C
for 40 - 50 s (Lee and Goosens 2015) and dried with a paper towel, followed by insertion of a
butterfly catheter into the tail for blood withdrawal. The butterfly catheter includes a tube that can
be manually attached to a syringe for stable blood withdrawal. The use of a butterfly catheter in
conjunction with giving isoflurane for anesthesia was less stressful for the rats, which was similarly
demonstrated by Lee and Goosens (2015).
To enable blood clot formation, blood (without anticoagulant) was placed into 0.6 mL
microcentrifuge tubes at room temperature for up to 30 min. The samples were placed in a
centrifuge at refrigerated (3 °C) conditions and spun at 2,000 g for 10 min (Lee and Goosens 2015).
The supernatant (serum) was transferred and stored at -80 °C until analysis.
Baseline blood samples were drawn at days 21 and 77, respectively, before and after effects
of a VDS diet and/or a VDD diet.
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3.4.5 Measurement of serum 25(OH)D concentration
Serum 25(OH)D levels were analyzed using Mouse/Rat 25-OH Vitamin D ELISA Assay
kit (Eagle Biosciences, Inc. Nashua, NH). Serum samples were diluted to fall within the range of
the calibration curve (10.9-144.7 ng mL-1) using 25(OH)D free zero calibrator provided in the
ELISA kit. Internal controls using serum from SD rats in the VDS-control (C1) group were
similarly diluted, used as representatives of the dilutions, and run in assays using the same kit
(intra-assay), and different kits (inter-assay) as shown in Figure 3.2.
3.4.6 Pharmacokinetic data analysis
For the pharmacokinetic data after a single high-dose of 300 µg, the corresponding Cmax,
tmax, and area under the curve (AUC) were determined. The tmax represents the time it takes post
dosing to reach a maximum 25(OH)D serum referred as Cmax (ng mL-1). AUC represents the
measure of systemic exposure to the drug in response to dose. The AUC of serum 25(OH)D
concentrations versus time profiles (0-48 h) was calculated using the trapezoidal method. The VD3
relative bioavailability of a treatment was calculated with respect to non-encapsulated VD3.
3.4.7 Data and statistical analysis
Serum 25(OH)D data were analyzed using mixed model analysis with the treatment and
gender as the between-subject effects while day or hour as the with-subject effects.
Diagnostic analysis was conducted on residuals to verify the model assumptions of normality and
equal variance. Rank data transformation was applied when the model assumptions were
violated. Multiple comparisons were performed with Tukey's adjust. Significance was identified
at 0.05. All analysis was conducted in SAS9.4 for Windows (SAS Institute, Cary, NC).

68

3.5 Results and discussion
3.5.1 Effect of diet on survival, overall health, and body weight of Sprague-Dawley rats
The animals tolerated the diet (VDS or VDD), and no death was attributed to dietary
manipulations. However, one male SD rat from VDD-capsules (T4) group was removed from the
study due to complications in anesthesia overdose prior to blood withdrawal. All other animals (n
= 59) survived until they were euthanized at the end of the study (108 d).
Our results showed dietary manipulations in SD rats fed either a VDS or a VDD diet did
not have any significant effect on body weight during and after the 8 wk feeding period (p > 0.05)
(Table 3.5). Furthermore, there were no obvious alterations in behavior (e.g., weakness or reduced
activity) during and after the induction of VDD compared to rats receiving VDS diet. The results
are in agreement with a similar study that used the same VDD diet (Stavenuiter and others 2015).
However, in the study by Stavenuiter and others (2015), the length of VDD induction through diet
manipulations was 5 wk, shorter than 8 wk in the present study. Furthermore, Wistar rats instead
of SD rats were used, and their rats additionally received intraperitoneal injections of 32 ng of 19nor-1,25-dihydroxyvitamin D2 (paricalcitol; Zemplar from Abbvie). Stavenuiter and others (2015)
had a more aggressive approach where the paricalcitol drug was used to accelerate the catabolism
of endogenous 25D and calcitriol storage with no reported adverse effects except for the intended
reduction on serum 25(OH)D.
VDD diet has compounding effects on mineral homeostasis in the body resulting to
hypocalcemia or hypophosphatemia (Holick 2003). Therefore, sufficient dietary mineral amounts
probably maintained balance in calcium and phosphorus levels, which may have resulted in no
significant difference in body weight between the VDS and VDD diet groups in our study. Both
diets contained 20% lactose, 2% calcium, and 1.25% phosphorus, a rescue diet formulated to
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counteract the absence of VD receptor (VDR) dependent intestinal Ca and P absorption, as
demonstrated in VDR-null mice (Scholz-Ahrens and others 2001; Bouillon and others 2008) by
enabling the parathyroid hormone to enhance bone formation (Toromanoff and others 1997;
Lieben and Carmeliet 2013).
3.5.2 Effect of dietary induced vitamin D deficiency or sufficiency
Comparison of serum 25(OH)D levels between treatment groups when SD rats were
weaned (21 d) and after an 8-wk dietary induced VDD or VDS is delineated in Figure 3.3. Serum
25(OH)D levels at weaning age (21 d) were not significantly different among all treatment groups.
After an 8-wk dietary treatment, serum 25(OH)D levels in rats fed a VDS diet (C1 and T3) did not
decrease on Day 77 in comparison to levels on Day 21, ranging between 72.18 to 83.93 ng mL-1.
In contrast, serum 25(OH)D levels in rats fed a VDD diet (C2, T1, T2, T4) decreased on Day 77
when compared to Day 21. Overall serum 25(OH)D level reductions from Day 21 to Day 77 on
rats that received a VDD diet were observed at ~52.35% in control (C2), ~42.65% in nonencapsulated (T1), ~38.95% in physical mixture (T2), and ~52.43% in capsules (T4). Despite
having significantly lower 25(OH)D levels than the VDS group (C1), the VDD rats (C2) were not
VD deficient according to the < 20 ng mL-1 (50 nmol L-1) cut-off established by the Institute of
Medicine (Ross and others 2011).
Other studies have successfully induced VDD within the 8 wk time frame. For example,
6-8 wks was sufficient in inducing VDD in mice corresponding to 25(OH)D levels of < 5 ng mL1

(Lagishetty and others 2010). Similarly, 6 wk induction of VDD in SD rats resulted to 10.9 ng

mL-1 25(OH)D levels (Angeline and others 2014). There are two possible explanations as to why
the VDD diet treatment groups did not have 25(OHD) levels fall below 20 ng mL-1. First, it is
possible that light exposure of the rats during the 12-h light/dark cycles in the animal facility may
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have influenced the VD serum levels. Second, endogenous breakdown of any VD stores may have
not been facilitated due to diet effect. The only other study that used the same food source and rat
light exposure was conducted by Stavenuiter and others (2015). In their study, rats fed a similar
diet containing 20% lactose, 2% Ca, and 1.25% P resulted in 6 ng mL-1 of 25(OH)D; however, rats
were also given an intraperitoneal injection of 32 ng of 19-nor-1,25-dihydroxyvitamin D2
(paricalcitol; Zemplar from Abbvie) which accelerated the catabolism of endogenous 25D and
calcitriol stores (Stavenuiter and others 2015).
Currently, there are no generally accepted consensus on optimal serum 25(OH)D levels
(Moulas and Vaiou 2018). Optimum 25(OH)D levels have been evaluated on a case by case basis.
For example, levels greater than 30 ng mL-1 but less than 100 ng mL-1 25(OH)D for children with
celiac disease have been recommended (Ahlawat and others 2017). In our study, the 25(OH)D
levels observed in the VDS control group (C1) after weaning age (78.9 ± 4.1 ng mL-1) fall within
the range of acceptable levels. The serum 25(OH)D level observed in the control group was high
and may be attributed to several reasons. For example, all animals were exposed to a 12-h light
and dark cycle in the animal facility. Furthermore, rats on average consumed 20 g of VDS pellet
food containing 2.2 IU VD/g diet (TD.96348), which would have led to a total 44 IU VD/day.
The serum 25(OH)D levels of the 2 control groups from Day 21 (weaning) to Day 108
(euthanization) showed different results (Table 3.8). As expected, rats fed a VDS diet (C1) did
not exhibit any reduction of serum 25(OH)D in the duration of the study (108 d) (p > 0.05).
However, the serum 25(OH)D levels of the VDD diet group (C2) decreased by 46.7 % from Day
21 to Day 108.
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3.5.3 Pharmacokinetics following a dose of 300 µg vitamin D3
The 25(OH)D levels of treatments measured at 2, 4, 8, 24 and 48 h post administration are
shown in Figure 3.4. Overall, capsule treatments (T3 and T4) resulted to better absorption of VD3
than non-encapsulated (T1) or physical mixture (T2) treatments. The significant increase from
42.09 ± 3.56 to 134.29 ± 39.13 ng mL-1 for the VDD-capsules treatment (T4) at the first 2-h time
point indicate the fast absorption of encapsulated VD3 (Table 3.6). Next, both the VDS-capsules
(T3) and VDD-physical mixture (T2) treatments had a significant increase of 25(OH)D levels at
4 h, followed by the VDD-non-encapsulated group (T1), which occurred at 24 h. The faster
absorption of VD by VDD rats than the VDS group was similarly observed by Boullata (2010).
The pharmacokinetic parameters are shown in Table 3.7. The relative bioavailability of
VD observed from the capsules treatments T3 and T4 was 4.54-fold and 4.32-fold of the nonencapsulated VD3 treatment (T1). However, T4 exhibited the shortest tmax (8 h) and Cmax of 659.13
ng mL-1; whereas, tmax of T3 occurred at 24 h with corresponding Cmax of 659.25 ng mL-1. The
VDD-physical mixture (T2) treatment had tmax a similar time (8 h) as that of T4 but had a lower
relative bioavailability, 2.05-fold of the non-encapsulated VD3 (T1). The increased absorption of
CoQ10 emulsified by GA based on AUC was also reported by Ozaki and others (2010). In their
study, emulsified CoQ10 had a relative bioavailability being 3-fold of the non-emulsified form and
had a tmax of 2 and 6 h after oral administration in SD rats and humans, respectively.
The relationship between oral dose of 300 µg to percent VD3 absorbed may be estimated
based on pharmacokinetic data. The amount of 25(OH)D in the blood is increased with the
continued VD3 absorption and is also decreased as it is cleared by the liver (Boullata 2010).
Considering 25(OH)D has a half-life of 15 days (Gropper and others 2009), the amount of

72

25(OH)D is expected to be similar between tmax and the next time point, and Cmax may be used to
estimate the percentage of VD3 absorbed based on Equation 1.
VD3 absorption (%) = [(Cmax -Cbaseline) x (VD3 MW /25(OH)D MW) x Wrats x (7.2 mL/100 g)] x 100

[1]

300,000 ng

Where: Cbaseline is the 25(OH)D level reported at hour 0 during the pharmacokinetics study (Table
3.6). VD3,MW and 25(OH)DMW corresponds to the molecular weight of VD3 and 25(OH)D,
respectively. Wrats is the average weight of rats on Day 78 (Table 3.5). The estimated blood
volume is ~7.2 mL/100 g SD rat (Probst and others 2006). The highest VD3 absorption was
observed in the VDD-capsule treatment (T4) corresponding to 4.05 %, followed by VDS-capsule
(T3) with 3.84%. VD3 absorption was lower in both the VDD-physical mixture treatment (T2)
and VDD-non-encapsulated treatment (T1), corresponding to 1.69 and 1.09%, respectively.
Benefits of capsule formulations are evident upon consumption of a single high-dose (300 µg)
when compared against efficacy of non-encapsulated or physical mixtures.
Pharmacologic effects of GA related to gastrointestinal absorption of nutrients have been
demonstrated in various studies (Ibrahim and others 2004; Nasir and others 2008; Ozaki and others
2010). For example, our findings on early onset of absorption in VDD-capsules treatment (T4) at
2 h post administration was similar to results obtained by Ozaki and others (2010) who studied
CoQ10 emulsified with GA. In their study, mixture of both compounds (CoQ10 and GA) was
performed under high-pressure homogenization at 900 kg cm2. The in vivo efficacy of emulsified
CoQ10 was performed on 6 wk old Sprague-Dawley rats (n=4) and tmax observed at 2 h postadministration; whereas, bulk CoQ10 had no peaks observed (Ozaki and others 2010). In another
study on SD rats, oral administration of an isotonic solution containing glutamate or
acetaminophen mixed with GA resulted in a rapid absorption of both compounds (tmax = 30 min),
suggesting that GA has pro-absorptive capability (Codipilly and Wapnir 2004). Similarly, isotonic
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mixture of zinc and GA yielded consistently higher blood zinc concentrations within 20 min after
administration than with GA-free solutions (Ibrahim and others 2004).
Increased bioavailability and quick uptake of lipophilic nutrients may be attributed to
several factors. First, increasing the water-solubility of lipophilic compounds through
encapsulation allows for “increased compatibility with the aqueous nature of the lining of the
digestive tract, thereby enhancing the bioavailability of the otherwise insoluble lipophilic
compound” (Diarrassouba and others 2015). Second, entrapment of VD3 in GA may lead to
enhanced interaction with bile salts with the compact GA structure opening at near neutral pH and
exposing the VD3 resulting to mass exchange to bile surfactant micelles and absorption.
Furthermore, the small particle dimensions of capsules in neutral pH may result in potential direct
absorption in the intestines (Inchaurraga and others 2019; Patel and others 2019).
3.5.4 Serum 25(OH)D levels during 2-week study with 60 µg vitamin D3 daily dose
To better understand the effect of VD supplementation, the same SD rats were given oral
gavage solutions of 60 µg d-1 for a period of 2 wks. A one-week “no VD3 treatment” period
between phase I (300 µg, single-dose) and phase II (60 µg d-1, 2 wks) was adapted to allow the
rats to have a resting period between the two-phases as illustrated in Figure 3.1.
Daily dose administration of 60 µg d-1 resulted in no significant change in 25(OH)D levels
on Day 89, 92, and 99 for the T3 and T4 treatments, corresponding to 346.88 and 359.57 ng mL-1
respectively. This 25(OH)D level is high in comparison with other studies that orally administered
higher VD3 amounts. For example, Wistrar rats fed 82.73 µg/d for 4 wks had plasma 25(OH)D
levels at 224.4 ± 52.4 ng mL-1 (Mirhosseini and others 2016). The VD used by Mirhosseini and
others (2016) was from a vegetarian source, and no other details was mentioned.
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There may be several contributing factors on the higher 25(OH)D levels observed in SD
rats that received capsules (T3 and T4). First, the absorption of VD3 is improved after
encapsulation in GA (Figure 3.4). Second, it is also possible that the consistently high 25(OH)D
levels may be attributed to the previously administered single-high dose of VD3 (300 µg)
administered on Day 78 because Day 89 and Day 92 fall within the 25(OH)D circulating half-life
of 15 days (Insel and Wardlaw 1996; Jones 2008). Specifically, 15 days after administration of
the single-high dose of 300 µg given on Day 78 would fall on Day 93. If the highest observed
25(OH)D levels for VDD-capsules treatment (T4) on Day 78 was at 659.13 (8 h) (Table 3.6),
~329.5 ng mL-1 25(OH)D would be an approximate estimate on Day 92 based on the half-life of
15 d. In fact, 335.79 ng mL-1 25(OH)D was observed for the VDD-capsules (T4) group on Day
92. The VDS-capsules (T3) group did not differ significantly from VDD-capsules (T4) on Day
92 (p > 0.05) showing a potential threshold in absorbed VD. In contrast, on Day 92, nonencapsulated (T1) (273.92 ng mL-1) and physical mixture (T2) (254.48 ng mL-1) had higher
25(OH)D levels when compared with ~109 and 153 ng mL-1, respectively.
Limited data are available on the comparative effects of oral supplementation of different
forms of VD (e.g., encapsulated vs non-encapsulated vs physical mixture) in rats. Therefore,
assessment of expected range of 25(OH)D increase in the animal is challenging. In humans,
additional of 100 IU VD3 per day raises serum 25(OH)D concentration by approximately 1 ng mL1

(Heaney and others 2011). Specific examples of 25(OH)D level increase after a daily VD3

supplementation in humans include the following: (1) an increase from baseline 23.0 to 33.0 ng
mL-1 after 3 month administration of 3,000-4,000 IU (75-100 µg) VD3 daily for human subjects
with an age of ≥ 60 yr (Ginde and others 2017); (2) an increase from baseline 20.1 to 65.7 ng mL1

after 3 month administration of 12,000 IU (300 µg) VD3 for human subjects with an age of 18 –
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45 yr (Raja-Khan and others 2014); (3) an increase from baseline 19.16 to 39.88 ng mL-1 6 weeks
post administration of a single oral dose of 200,000 IU (5,000 µg) VD3 for human subjects with
an age of ≥ 18 yr (Slow and others 2018). Overall estimation of expected 25(OH)D level increase
cannot be generalized even for healthy adults because other non-age factors e.g., diet, disease, and
health status can influence the metabolism of orally consumed VD. In addition, matrices that
provide protection against gastric stomach pH for target delivery in the small intestines (Cohen
and others 2017) may also lead to higher absorbed VD in relation to dose response.
There was a period of ten days (Day 99 – Day 108) of “no treatment” after the last 60 µg
VD3 was administered to the SD rats. On Day 108, rats were euthanized and no significant
differences in 25(OH)D levels were observed between VDD-non-encapsulated (T1), VDScapsules (T3), and VDD-capsules groups (T4) (p > 0.05). In contrast, the VDD-physical mixture
(T2) group exhibited significantly higher 25(OH)D levels on Day 108 when compared with all
other treatments (p < 0.05). According to pharmacokinetics (Figure 3.4), the encapsulated VD3
is expected to be absorbed better than the physical mixture of VD3 and GA. The mechanism
leading to the unexpected observation is to be studied.
3.6 Conclusion
The development of VD3-GA capsules for use as a food-grade ingredient to enhance the
absorption of VD3 was demonstrated in this study. The VD3 encapsulated in GA significantly
increased the concentration of 25(OH)D in blood of SD rats compared to the non-encapsulated
VD3.

Specifically, after a single high-dose oral gavage, the relative bioavailability of VD3 in

capsules was at least 4-fold of the non-encapsulated VD3 and the absorption of VD3 encapsulated
in GA was faster than the physical mixture or non-encapsulated VD3 formulations. In contrast,
treatments of daily dose of 60 µg VD3 resulted in equal 25(OH)D levels between capsules and
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physical mixture at 2 weeks supplementation, which may have been complicated by the long halflife of 25(OH)D and the insufficient delay between the two-phase studies. After 10 days since the
last administration of the low-dose treatment, serum 25(OH)D levels were similar between all
treatment groups except the physical mixtures of GA and VD3 with higher 25(OH)D. This study
showed that GA is a good excipient for use as a bioactive absorption enhancer to improve the
absorption of VD3.
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Appendix

Figure 3.1. General schematic design of the in vivo study.
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Table 3.1. Dietary composition of vitamin D sufficient (VDS) pellet food a (TD.96348, Envigo, Teklad Custom Diet, Madison, WI).
Formula b

g/Kg

Casein, “Vitamin-Free” Test
192.0
DL-Methionine
3.0
Sucrose
264.78
Lactose, monohydrate
200.0
Corn Starch
150.0
Corn Oil
50.0
Cellulose
50.0
Vitamin Mix, Teklad (40060)
10.0
Mineral Mix, AIN-76 (170915)
35.0
Calcium Phosphate, dibasic
31.17
Calcium Carbonate
14.05
c
Selected Nutritional Information
% by weight
Protein
17.6
Carbohydrate
59.8
Fat
5.0
Kcal/g
3.5
a
Irradiated
b
Referred to in the literature as a rescue diet for mice lacking a functional vitamin D receptor. Contains approximately 2200 IU
vitamin D/kg diet, along with 20% lactose, 2.0% calcium, and 1.25% phosphorus. TD. 87095 is a version without vitamin D that is
colored brown.
c
Values are calculated from ingredient analysis or manufacturer data
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Table 3.2. Dietary composition of vitamin D deficient (VDD) pellet food a (TD.87095, Envigo, Teklad Custom Diet, Madison, WI).
Formula b

g/Kg

Casein, “Vitamin-Free” Test
DL-Methionine
Sucrose
Lactose, monohydrate
Corn Starch
Corn Oil
Cellulose
Mineral Mix, AIN-76 (170915)
Calcium Phosphate, dibasic
Calcium Carbonate
Vitamin Mix, w/o choline, A, D, E (83171)
Choline Dihydrogen Citrate
Vitamin E, DL-alpha tocopheryl acetate (1000 IU/g)
Vitamin A Palmitate (200,000 IU/g in oil)
Brown Food Color
Selected Nutritional Information c

192.0
3.0
264.78
200.0
151.28
50.0
50.0
35.0
31.17
14.05
5.0
3.5
0.121
0.0991
0.1
% by weight

Protein
Carbohydrate
Fat
Kcal/g
a
Irradiated and does not include vitamin D
b
Values are calculated from ingredient analysis or manufacturer data

17.6
59.8
5.0
3.5

85

Table 3.3. The designed and actual masses of ingredients used in Phase I in vivo pharmacokinetics study.*
Diet

Formulation

Designed mass

Actual mass

VD3 powder GA powder Freeze-dried
VD3- GA
capsules

VD3

GA

Freeze-dried
VD3- GA
capsules

Control (C1)

-

5.46 mg

-

5.61 ± 0.10 mg

-

Capsules (T3)

-

-

5.76 mg

-

-

5.87 ± 0.06 mg

Control (C2)

-

5.46 mg

-

-

5.61 ± 0.10 mg

-

Non-encapsulated

300 μg

-

-

312.0 ± 5.66 μg

-

-

300 μg

5.46 mg

-

313.67 ± 9.29 μg

5.61 ± 0.04 mg

-

-

-

5.76 mg

-

-

5.87 ± 0.06 mg

VDS

VDD

(T1)
Physical Mixture
(T2)
Capsules (T4)

* A dash (-) indicates not applicable. Actual mass represents mean ± SD (n = 10). Freeze-dried capsule powder contains 5.21%
VD3 as quantified in normal-phase HPLC.
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Table 3.4. The designed and actual masses of ingredients used in Phase II in vivo daily-dose for 2 wks study.*
Diet

Formulation

Designed mass
VD3 powder GA powder

Actual mass
Freeze-dried
VD3- GA
capsules

VD3

GA

Freeze-dried
VD3- GA
capsules

-

1.13 ± 0.10 mg

-

VDS
Control (C1)

-

1.11 mg

Capsules (T3)

-

-

1.15 mg

-

-

1.18 ± 0.06 mg

Control (C2)

-

1.11 mg

-

-

1.13 ± 0.10 mg

-

Non-encapsulated (T1)

60 μg

-

-

64.8± 5.66 μg

-

-

Physical Mixture (T2)

60 μg

1.11 mg

-

64.2 ± 9.29 μg

1.19 ± 0.04 mg

-

Capsules (T4)

-

-

1.15 mg

-

-

1.18 ± 0.06 mg

VDD

* A dash (-) indicates not applicable. Actual mass represents mean ± SD (n=10). Freeze-dried capsule powder contains 5.21%
VD3 as quantified in normal-phase HPLC.
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Figure 3.2. General schematic on oral gavage administration of formulations, animal and blood collection, serum separation and analysis.
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Table 3.5. Mean body weight of SD rats at age 21, 78, and 108 day in corresponding treatment groups.*
Rat age (day)

VDS Diet
Control 1

VDD Diet
Capsules (T3)

Control 2 (C2)

(C1)

Non-

Physical

encapsulated

Mixture (T2)

Capsules (T4)

VD3 (T1)
21 (weaning)

47.82 ± 6.10

47.21 ± 6.53

47.61 ± 7.03

43.11 ± 3.99

46.11 ± 5.05

51.64 ± 7.06

78

281.02 ± 15.24

289.64 ± 24.41

283.88 ± 23.13

269.55 ± 15.28

285.75 ± 15.92

284.97 ± 22.07

302.72 ± 18.80

318.16 ± 28.20

307.67 ± 28.06

301.35 ± 17.19

301.73 ± 17.72

312.66 ± 25.24

(pharmacokinetics
study)
108
(euthanization)
* Numbers are mean ± S.E.M. No significant difference in body weight between treatments on the same day (P > 0.05).
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Figure 3.3. Mean serum 25(OH)D of SD rats on weaning (day 21) and after 8 wk dietary treatment (day 77, baseline) for the two controls
and 4 treatment groups.
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Figure 3.4. Pharmacokinetic profile in 25(OH)D concentrations after administration of 300 µg VD3 in the capsules (dispersed in
phosphate buffer), physical mixture (VD3 pre-dissolved in propylene glycol and gum arabic in phosphate buffer), or non-encapsulated
(pre-dissolved in propylene glycol) forms. The control treatments are fed with the same amount of gum arabic dissolved in phosphate
buffer. Rats were fed with VD deficient (VDD) or sufficient (VDS) diets. Error bars are S.E.M. (n=10).
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Table 3.6. Pharmacokinetic data in 25(OH)D levels (ng/mL) for different treatments (same data in Fig. 3.4).*
Diet and
Treatment

Time after gavage (h)
0

2

4

8

24

48

Control (C1)

72.18 ± 4.96 A, a

78.28 ± 5.68 B, a

70.84 ± 6.82 B, a

80.36 ± 6.15 C, a

73.27 ± 6.44 C, a

70.77 ± 3.97 C, a

Capsules (T3)

83.93 ± 5.52 A, c

119.53 ±14.94 A, c

329.24 ± 65.32 A, b

629.15 ± 46.06 A, a

659.25 ± 36.27 A, a

537.57 ± 29.61 A, a

Control 2 (C2)

38.33 ± 3.27 B, a

40.31 ± 3.30 C, a

49.56 ± 6.84 C, a

35.87 ± 2.09 D, a

38.96 ± 3.22 C, a

38.66 ± 2.36 D, a

Nonencapsulated
(T1)
Physical

43.33 ± 2.83 B, d

47.20 ± 2.31 C, d, c

55.97 ± 6.99 C, b, c

62.90 ± 3.66 C, b

121.78 ± 18.78 B, a

218.64 ± 56.41 B, a

50.37 ± 3.07 B, d

83.30 ± 17.52 B, c

176.73 ± 57.15 B, b

306.80 ± 88.49 B, a

260.11 ± 88.94 B, a

274.28 ± 70.81 B, a

42.09 ± 3.56 B, e

134.29 ± 39.13 A, d

367.51 ± 62.50 A, c

659.13 ± 42.74 A, a

605.17 ± 52.65 A, b

482.83 ± 23.89 A, c

VDS Diet

VDD Diet

Mixture (T2)
Capsules (T4)

* Numbers are mean ± S.E.M. (n=10). Different uppercase superscript letters in the same column are significantly different (P <
0.05). Different lowercase superscript letters in the same row are significantly different (P < 0.05).
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Table 3.7. In vivo pharmacokinetic parameters following 300 µg VD3 oral administration to Sprague-Dawley rats.
Pharmacokinetic

VDD Diet

VDS Diet

VDD Diet

parameters

Non-encapsulated (T1)

Capsules (T3)

Physical

Mixture Capsules (T4)

(T2)
t max (h)

48

24

8

8

C max (ng mL-1)

218.64 ± 56.41

659.25 ± 36.27

306.80 ± 88.49

659.13 ± 42.74

AUC (ng ml-1.h) #

5,994

27,238

12,309

25,902

Relative

1.00

4.54

2.05

4.32

Bioavailability *
#

Area under curve of serum 25(OH)D concentrations versus time profiles (0-48 h), calculated using the trapezoidal method.
Ratio of the area under curve of 25(OH)D concentrations versus time profiles, calculated as AUC (0-48 h) of treatment / AUC (0-48 h)
of non-encapsulated VD3.
*
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Table 3.8. Serum 25(OH)D (ng/mL) level of Sprague-Dawley rats at weaning age (day 21), during 2-week daily-dose of 60 µg VD3
treatments (day 85-98, measured on days 89, 92, 99), post-treatment (day 106), and on euthaenization (day 108).*
Diet and

Serum 25(OH)D level (ng/mL)

Treatment
Day 21

Day 89

Day 92

Day 99

Day 106

Day 108

Control (C1)

75.77 ± 4.36 A, a

76.78 ± 5.45 C, a

79.49 ± 6.10 C, a

79.32 ± 4.98 C, a

86.02 ± 5.03 B, a

77.32 ± 4.62 C, a

Capsules (T3)

77.08 ± 3.02 A, c

350.96 ± 21.18 A, a

345.78 ± 19.27 A, a

343.90 ± 17.75 A, a

168.55 ± 15.70 A, b

143.21 ± 6.95 B, b

Control (C2)

80.44 ± 4.46 A, a

34.02 ± 4.08 D, b

34.31 ± 3.93 D, b

59.44 ± 11.99 D, c

47.70 ± 5.65 C, c, d

41.56 ± 4.69 D, d

Non-encapsulated

75.37 ± 4.25 A, e

200.48 ± 33.63 B, b

273.92 ± 30.70 B, a

262.88 ± 23.77 B, a

175.98 ± 13.07 A, c

144.29 ± 9.98 B, d

82.51 ± 4.47 A, c

239.80 ± 54.06 B, b

254.48 ± 45.50 B, b

434.79 ± 43.37 A, a

209.32 ± 18.17 A, b

210.18 ± 25.33 A, b

88.48 ± 2.61 A, d

347.90 ± 8.93 A, a

335.79 ± 12.34 A, a

395.02 ± 24.01 A, a

182.67 ± 20.81 A, b

135.60 ± 9.69 B, c

VDS Diet

VDD Diet

(T1)
Physical Mixture
(T2)
Capsules (T4)

* Numbers are mean ± S.E.M. (n=10). Different uppercase superscript letters in the same column are significantly different (P <
0.05). Different lowercase superscript letters in the same row are significantly different (P < 0.05).
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Chapter 4 Concluding remarks and future directions
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4.1 Conclusions
In conclusion, this dissertation demonstrated that VD3 was successfully encapsulated in
gum arabic (GA) with an encapsulation efficiency of 71.35% and a loading capacity of 3.44%.
Capsules were stable across a wide pH range between 2.0 and 7.4 even after 100-d storage at 3 °C.
In vitro digestion results showed capsules to be more bioaccessible than non-encapsulated VD3
(95.8% vs 69.0%, respectively). Oral administration of capsules leads to faster and improved
absorption of VD3 in Sprague-Dawley rats. The fast absorption was significant and occurred
within 2 hrs post oral gavage of capsules. The clinical significance of rapidly increasing 25(OH)D
levels had a greater impact on SD rats on a VDD rather than a VDS diet. Interestingly,
administering lower VD3 doses of 60 µg resulted to similar absorption for both capsules and that
of the physical mixture after a 2 wks daily dose regimen.
This study provides valuable insight on potential enhancement of VD3-GA interaction with
bile in the small intestinal mucosa. By using GA to encapsulate VD3, interaction with bile salts
may have been facilitated leading to faster absorption of VD3. Once inside the intestinal cells, the
vitamin is transported in the blood by interaction with chylomicrons where it then makes its way
to the liver, resulting to the higher observed levels of 25(OH)D.

The overall improvements in

solubility, pH stability, and VD3 bioavailability when entrapped in a GA matrix makes this
emulsifier a good excipient for delivery of hydrophobic bioactive compounds in foods and
beverages.
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4.2 Future work
The capsules in our study showed excellent physicochemical properties and high
absorption in SD rats. However, effects of the high VD3 dose should be evaluated for potential
toxicological effects. Toxicity is referred to as hypervitaminosis D with clinical symptoms that
include nausea, vomiting, and weakness (Blank and others 1995). The SD rats did not exhibit any
of these symptoms after the one-time high dose of 300 µg or the 2-wk daily dose of 60 µg VD3.
However, VD regulates calcium and phosphorus homeostasis and can therefore be measured to
determine the dosing regimen effect on animal health. Excess VD promotes bone calcium to return
to the blood. When there is excess blood calcium, precipitation in soft tissues, known as
calcification occurs. Calcium deposits result to formation of kidney stones and hardening of blood
vessels leading to irreversible damage (Gropper and others 2009). The VD dose administered to
the rats is highly interconnected with the amount of phosphorus in the blood. An excess of VD
will lead to an increase in blood phosphate levels. The relationship of elevated calcium to
phosphorus is that ionized Ca concentration affects the amount of PTH secreted. At high levels of
calcium, release of PTH hormone falls (Insel and Wardlaw 1996; Gil and others 2018).
For future studies, oral administration of encapsulated VD3 in GA should include
determining the impact on gut microbiota as we regret that this was not examined in this study.
GA is a prebiotic, meaning it is a dietary substance that proliferates enteric bacteria (Saez-Lara
and others 2015). Prebiotics are defined as a food ingredient that is not digested by the host but is
fermented by intestinal microflora (Scholz-Ahrens and others 2001). GA is fermented by intestinal
bacteria to produce short-chain fatty acids (SCFAs) in the large intestine and acts a prebiotic at a
dose of 10 g/day (Phillips and others 2008).
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